B-cell lymphoma 2-associated immortalized gene 3 (BAG3) gene therapy using AAV vectors
Delivering the BAG3 gene through gene therapy vectors solves the cardiomyopathy and heart failure caused by BAG3 loss of function, significantly improves cardiac function and prolongs the lifespan of heart cells.
Patent Information
- Application Number
- CN202380035629.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-22
- Filing Date
- 2023-04-21
- Publication Date
- 2024-12-03
AI Technical Summary
The existing treatment methods have limited effect on patients with BAG3-related cardiomyopathy and heart failure, especially heart disease caused by genetic loss has not been effectively solved.
Using a gene therapy vector, the BAG3 gene is introduced into cardiomyocytes using an AAV vector to restore or enhance BAG3 expression by delivering a polynucleotide encoding a BAG3 polypeptide or a functional variant thereof.
It significantly improves the expression of BAG3 protein in cardiomyocytes, improves cardiac function, slows the progression of heart failure and cardiomyopathy, prolongs the lifespan of heart cells, and reduces the risk of arrhythmia and sudden death.
Smart Images

Figure CN119072323A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 333,798, filed on April 22, 2022, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Statement regarding sequence listing
[0002] The sequence listing XML associated with this application is provided in XML file format and is hereby incorporated into this specification by reference. The name of the XML file containing the sequence listing is ROPA_028_01WO_SeqList_ST26.xml. The XML file is 156,193 bytes and was created on April 19, 2023, and was submitted electronically via the USPTO Patent Center. Background Art
[0003] Heart failure and cardiomyopathy are both serious life-threatening diseases. Loss-of-function mutations in the gene B-cell Lymphoma 2–Associated Anthanogene 3 (BAG3) have been shown to cause cardiomyopathies such as dilated cardiomyopathy (DCM), including BAG3-related DCM, BAG3-related myofibrillar myopathy, familial isolated DCM, and dilated 1hh cardiomyopathy (CMD1HH). Downregulation of BAG3 is also associated with cardiac dysfunction and heart failure.
[0004] BAG3 mediates chaperone-assisted autophagy by acting as a co-chaperone with Hsp70, blocks apoptosis by coupling with Bcl-2, maintains sarcomere integrity by coupling actin filaments to Z-lines, and enhances beta-agonist-stimulated excitation-contraction by linking beta-adrenergic receptors to L-type Ca2+ channels. BAG3 downregulation disrupts the chaperone-assisted selective autophagy (CASA) complex, which mediates turnover of cardiac proteins such as filamin C.
[0005] Current treatment modalities, including pharmacological therapy and cardiac ablation, remain ineffective for patients with BAG3-deficient cardiomyopathy. Therefore, there remains an unmet need in the art for the treatment of BAG3-related diseases and conditions, including cardiomyopathy and other cardiac conditions. The compositions and methods disclosed herein address this need. Summary of the invention
[0006] The present invention generally relates to gene therapy vectors and gene therapy for diseases or disorders (eg, heart diseases or disorders) using vectors expressing BAG3 or functional variants thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0007] Figure 1 107 is a diagram showing a non-limiting example of a vector genome. The complete polynucleotide sequence of the vector genome is SEQ ID NO: 107.
[0008] Figure 2 1 is a diagram showing a non-limiting example of a vector genome. The complete polynucleotide sequence of the vector genome is SEQ ID NO: 108.
[0009] Figure 3 109 is a diagram showing a non-limiting example of a vector genome. The complete polynucleotide sequence of the vector genome is SEQ ID NO: 109.
[0010] Figure 4 is a diagram showing a non-limiting example of a vector genome. The complete polynucleotide sequence of the vector genome is SEQ ID NO:110.
[0011] Figure 5 FIG. 1 is a diagram showing a non-limiting example of a vector genome. The complete polynucleotide sequence of the vector genome is SEQ ID NO: 111.
[0012] Figure 6 FIG. 1 is a diagram showing a non-limiting example of a vector genome. The complete polynucleotide sequence of the vector genome is SEQ ID NO: 112.
[0013] Figure 7 FIG. 1 is a diagram showing a non-limiting example of a vector genome. The complete polynucleotide sequence of the vector genome is SEQ ID NO: 113.
[0014] Figure 8 1 is a diagram showing a non-limiting example of a vector genome. The complete polynucleotide sequence of the vector genome is SEQ ID NO:114.
[0015] Figure 9 Shown is the expression of BAG3 in CHO-Lec2 cells after transduction with the indicated vectors. Cells were transduced with an MOI of 3E6 for each vector, and 6 days later, cell lysates were collected and subjected to Western blot analysis using an anti-BAG3 polyclonal antibody (abcam ab225561 1:2,500). DETAILED DESCRIPTION
[0016] The present invention provides gene therapy vectors and methods of use and other compositions and methods for delivering polynucleotides encoding BAG3 polypeptides or their functional fragments or variants. In a specific embodiment, the present invention relates to a gene therapy vector comprising a promoter sequence operably linked to a polynucleotide encoding a BAG3 polypeptide or its functional fragments or variants. In certain embodiments, the promoter is a heterologous promoter, that is, it is not a normal or endogenous promoter of the BAG3 gene in a mammalian cell, or it is not a normal or endogenous protein of a gene delivery vector (e.g., AAV). In some embodiments, BAG3 is human BAG3.
[0017] In some embodiments, the AAV vector is an AAVrh.74 vector. In some embodiments, the promoter is the MHCK7 promoter and the AAV vector is an AAVrh.74 vector. In some embodiments, the promoter is the hTNNT2 promoter. In some embodiments, the promoter is the hTNNT2 promoter and the AAV vector is an AAVrh.74 vector. In some embodiments, the promoter is the HSP70 promoter. In some embodiments, the promoter is the HSP70 promoter and the AAV vector is an AAVrh.74 vector. In some embodiments, the promoter is the ubiquitin C (UBC) promoter. In some embodiments, the promoter is the UBC promoter and the AAV vector is an AAVrh.74 vector. In some embodiments, the promoter is the CAG promoter or the chicken beta actin promoter. In some embodiments, the promoter is the CAG promoter or the chicken beta actin promoter and the AAV vector is an AAVrh.74 vector. In some embodiments, BAG3 is human BAG3.
[0018] In some embodiments, the AAV vector is an AAV9 vector. In some embodiments, the promoter is the myosin heavy chain creatine kinase 7 (MHCK7) promoter. In some embodiments, the promoter is the MHCK7 promoter, and the AAV vector is an AAV9 vector. In some embodiments, the promoter is the hTNNT2 promoter. In some embodiments, the promoter is the hTNNT2 promoter and the AAV vector is an AAV9 vector. In some embodiments, the promoter is the heat shock protein 70 (HSP70) promoter. In some embodiments, the promoter is the HSP70 promoter and the AAV vector is an AAV9 vector. In some embodiments, the promoter is the ubiquitin C (UBC) promoter. In some embodiments, the promoter is the UBC promoter and the AAV vector is an AAV9 vector. In some embodiments, the promoter is the CAG promoter or the chicken beta actin promoter. In some embodiments, the promoter is the CAG promoter or the chicken beta actin promoter and the AAV vector is an AAV9 vector. In some embodiments, BAG3 is human BAG3.
[0019] The disclosure further provides a method for treating a disease or condition of a subject by administering a gene therapy vector of the disclosure to the subject. In certain embodiments, the disease or condition is heart failure. In certain embodiments, the disease or condition is a cardiomyopathy, such as dilated cardiomyopathy. In certain embodiments, the disease or condition is BAG3-related dilated cardiomyopathy, BAG3-related myofibrillar myopathy, familial isolated dilated cardiomyopathy, and dilated 1hh cardiomyopathy (CMD1HH).
[0020] In certain embodiments, the treated subject is a heart failure patient with one or more mutations or truncations in the BAG3 gene. The expression of BAG3 is reduced in the gradually failing heart of a variety of etiologies (including human heart failure). Gene BAG3 encodes protein B cell lymphoma 2-associated immortality gene 3 (BAG3). BAG3 is related to protein quality control (PQC). PQC includes chaperones and protein degradation systems, including ubiquitin-proteasome system (UPS) and autophagy lysosome system that help to minimize protein toxicity. Chaperones act as the first line of defense by refolding misfolded proteins or by promoting the degradation of misfolded or damaged proteins that are not suitable for refolding via UPS or autophagy. BAG3 regulates the ATPase activity of a class of chaperones (HSP70 family) and is mainly expressed in striated muscle.
[0021] BAG3 is also involved in chaperone-assisted selective autophagy (CASA). CASA is a cargo-selective form of autophagy that is mediated by the HSC70-BAG3-HSPB8 complex and allows ubiquitination of selected proteins recognized by HSC70 via the CHIP ubiquitin ligase and sequestration by the autophagosome via the LC3 adaptor p62 / SQSTM in the presence of synaptopodin 2 or DNAJB6. In muscle, BAG3 is particularly important for maintaining the structure and integrity of the sarcomere through its interaction with HSC70 and the actin cap sarcomeric protein (actin cap protein β1).
[0022] Genome-wide association studies (GWAS) have identified several mutations in BAG3, such as E455K, in DCM patients. In addition, mouse models (e.g., BAG3 cKO or BAG3 E455K KI) have shown that functional loss of BAG3 induces the development of DCM by attenuating PQC within a specific subset of proteins associated with the metabolic and contractile function of cardiomyocytes.
[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although methods and materials similar to or equivalent to the methods and materials described herein can be used to practice or test the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples described herein are illustrative only and are not intended to be limiting.
[0024] All publications and patents mentioned herein are incorporated herein by reference in their entirety, as if each individual publication or patent was specifically and individually indicated to be incorporated herein by reference. In the event of a conflict, the present application (including any definitions herein) will control. However, the mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not and should not be taken as an admission or any form of representation that it constitutes valid prior art or forms part of the common general knowledge in any country in the world.
[0025] In this specification, unless otherwise indicated, any concentration range, percentage range, ratio range or integer range should be understood to include any integer value and (where appropriate) its fraction (such as one tenth and one hundredth of an integer) within the listed range. The term "about" when directly before a number or numeral means an integer or numerical range plus or minus 10%. It should be understood that, unless otherwise indicated, the terms "a" and "an" as used herein refer to "one or more" of the listed components. It should be understood that the use of alternatives (such as "or") means one, both or any combination of the alternatives. The term "and / or" should be understood to mean one or both of the alternatives. As used herein, the terms "include" and "comprise" are used synonymously.
[0026] As used herein, the term "over time in a subject" refers to an effect occurring in a subject that lasts for about a day, about a month, about a year, about ten years, and / or about several decades.
[0027] As used herein, with respect to polypeptide or polynucleotide sequences, the terms "identity" and "identical" refer to the percentage of exactly matching residues in an alignment of the "query" sequence with a "subject" sequence (such as an alignment generated by the BLAST algorithm). Unless otherwise stated, identity is calculated over the full length of the subject sequence. Thus, a query sequence has "at least x% identity" to a subject sequence if, when the query sequence is aligned with the subject sequence, at least x% (rounded down) of the residues in the subject sequence are exactly matched to the corresponding residues in the query sequence. When the subject sequence has variable positions (e.g., residues marked as X), alignment with any residue in the query sequence is considered a match. Sequence alignments can be performed using the NCBI Blast service (BLAST+ version 2.12.0).
[0028] As used herein, the term "operably connected" refers to the functional relationship between two or more nucleic acid (e.g., DNA) segments. Generally, it refers to the functional relationship of a transcription regulatory sequence relative to a transcribed sequence. For example, if a promoter sequence stimulates or regulates the transcription of a coding sequence in a suitable host cell or other expression system, it is operably connected to the coding sequence. In general, a promoter transcription regulatory sequence that is operably connected to a transcribed sequence is physically adjacent to the transcribed sequence, i.e., it is cis-acting. However, some transcription regulatory sequences such as enhancers do not need to be physically adjacent to or in close proximity to the coding sequence that enhances transcription.
[0029] As used herein, "AAV vector" or "rAAV vector" refers to a recombinant vector comprising one or more polynucleotides of interest (or transgenes) flanked by AAV inverted terminal repeats (ITRs). Such AAV vectors can be replicated and packaged into infectious viral particles (when present) in host cells transfected with plasmids encoding and expressing rep and cap gene products. Alternatively, AAV vectors can be packaged into infectious particles using host cells that have been stably engineered to express rep and cap genes.
[0030] As used herein, "AAV virion" or "AAV virus particle" or "AAV vector particle" refers to a virus particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. As used herein, if the particle contains a heterologous polynucleotide (i.e., a polynucleotide other than the wild-type AAV genome (such as a transgene to be delivered to a mammalian cell)), it is generally referred to as an "AAV vector particle" or simply "AAV vector". Therefore, the production of AAV vector particles necessarily includes the production of AAV vectors, and the vectors are therefore contained within AAV vector particles.
[0031] As used herein, "promoter" refers to a polynucleotide sequence capable of promoting the initiation of RNA transcription from a polynucleotide in a eukaryotic cell.
[0032] As used herein, "vector genome" refers to a polynucleotide sequence encapsulated by a vector (e.g., rAAV viral particles), which includes flanking sequences (in AAV, inverted terminal repeats). The terms "expression cassette" and "polynucleotide cassette" refer to the portion of a vector genome between flanking ITR sequences. "Expression cassette" means that the vector genome comprises at least one gene encoding a gene product operably linked to an element driving expression (e.g., a promoter).
[0033] As used herein, the term "patient in need" or "subject in need" refers to a patient or subject who is at risk of or suffering from a disease, disorder or condition that can be treated or improved with the recombinant gene therapy vector or gene editing system disclosed herein. A patient or subject in need may, for example, be a patient or subject diagnosed with a heart-related disorder. The subject may have a BAG3 gene mutation or a complete or partial deletion of the BAG3 gene or gene regulatory sequence, which causes an abnormal interaction between BAG3 and HSP70. "Subject" and "patient" are used interchangeably herein. The subject treated by the methods described herein may be an adult or a child. The age of the subject may be different.
[0034] As used herein, the term "variant" refers to a protein having one or more amino acid substitutions, insertions or deletions compared to a parent protein. As used herein, the term "functional variant" refers to a protein having one or more amino acid substitutions, insertions or deletions compared to a parent protein and retaining one or more desired activities of the parent protein.
[0035] As used herein, "BAG3", "BAG3 molecule", "BCL2-associated immortality gene 3 (BAG3) gene", "BCL2-associated immortality gene 3 (BAG3) molecule" include all family members, mutants, cDNA sequences, alleles, fragments, substances, coding and non-coding sequences, sense and antisense polynucleotide chains, etc. Similarly, "BAG3", "BAG3 molecule", "BCL2-associated immortality gene 3 (BAG3) molecule" also refers to BAG3 polypeptides or fragments, proteins, variants, derivatives, etc. thereof. Unless otherwise specified, the term "molecule" covers the nucleic acid sequence and amino acid sequence of BAG3.
[0036] As used herein, the term "fragment" refers to a protein fragment. As used herein, the term "functional fragment" refers to a protein that has one or more deletions compared to a parent protein and retains one or more desired activities of the parent protein. In a particular embodiment, a fragment may be a portion of an N-terminal and / or C-terminal extension that lacks amino acids in a protein. A fragment may contain less than 99%, less than 95%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, or less than 20% of the full-length protein.
[0037] As used herein, "treating" refers to ameliorating one or more symptoms of a disease or disorder. The term "preventing" refers to delaying or inhibiting or interrupting the onset of one or more symptoms of a disease or disorder or slowing the progression of a BAG3-related disease or disorder (eg, dilated cardiomyopathy (DCM)).
[0038] Adeno-associated virus (AAV) is a replication-deficient parvovirus with a single-stranded DNA genome of approximately 4.7 kb in length, including two inverted terminal repeats (ITRs) of approximately 145 nucleotides. There are multiple known variants of AAV, sometimes referred to as serotypes, when classified by antigenic epitopes. The nucleotide sequences of the genomes of known AAV serotypes. For example, the complete genome of AAV-1 is provided as GenBank Accession No. NC_002077; the complete genome of AAV-2 is provided as GenBank Accession No. NC_001401 and is provided in Srivastava et al., J. Virol., 45:555-564 (1983); the complete genome of AAV-3 is provided as GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided as GenBank Accession No. NC_001829; the genome of AAV-5 is provided as GenBank Accession No. AF085716; the complete genome of AAV-6 is provided as GenBank Accession No. NC_001862; at least portions of the genomes of AAV-7 and AAV-8 are provided as GenBank Accession Nos. AX753246 and AX753249, respectively; the genome of AAV-9 is provided in Gao et al., J. Virol., 45:555-564 (1983). al., J. Virol., 78:6381-6388 (2004); the AAV-10 genome is provided in Mol. Ther., 13 (1): 67-76 (2006); and the AAV-11 genome is provided in Virology, 330 (2): 375-383 (2004). The sequence of the AAVrh.74 genome is provided in U.S. Pat. No. 9,434,928, which is incorporated herein by reference. The cis-acting sequences (rep) that direct viral DNA replication, encapsidation / packaging, and host cell chromosome integration are contained within the AAV ITRs. Three AAV promoters (named p5, p19, and p40 for their relative map positions) drive expression of two AAV internal open reading frames encoding the rep and cap genes. Two rep promoters (p5 and p19) combined with differential splicing of a single AAV intron (at nucleotides 2107 and 2227) will result in the production of four rep proteins (rep78, rep68, rep52, and rep40) from the rep gene. The rep proteins have multiple enzymatic properties that are ultimately responsible for replicating the viral genome. The cap gene is expressed by the p40 promoter and encodes three capsid proteins, VP1, VP2, and VP3. Alternative splicing and non-common translation start sites are responsible for the production of three related capsid proteins. A single common polyadenylation site is located at map position 95 of the AAV genome.The life cycle and genetics of AAV are reviewed in Muzyczka, Current Topics in Microbiology and Immunology, 158:97-129 (1992).
[0039] AAV has unique characteristics, making it an attractive vector for delivering foreign DNA to cells, such as in gene therapy. AAV does not cause cytopathic effects when infecting cells in culture medium, and is silent and asymptomatic for natural infection in humans and other animals. In addition, AAV infects a variety of mammalian cells, making it possible to target a variety of different tissues in vivo. In addition, AAV slowly transduces dividing cells and non-dividing cells, and can substantially maintain the form of transcriptionally active nuclear free genomes (extrachromosomal elements) during the life of these cells. The AAV viral genome is inserted into a plasmid as cloned DNA, which makes it possible to construct a recombinant genome. In addition, since the signal for directing AAV replication and genomic capsids is contained in the ITR of the AAV genome, some or all of the internal approximately 4.7kb of the genome (encoding replication and structural capsid proteins, rep-cap) can be replaced by foreign DNA. To produce AAV vectors, rep and cap proteins can be provided in a trans-acting manner. Another notable feature of AAV is that it has high thermal stability. It readily withstands the conditions used to inactivate adenovirus (56°C to 65°C for several hours), making cryopreservation of AAV less critical. AAV can even be lyophilized. Finally, AAV-infected cells are not resistant to repeated infection.
[0040] Gene delivery viral vectors that can be used to implement the present invention can be constructed using methods known in molecular biology techniques. Typically, viral vectors carrying transgenes are assembled from polynucleotides encoding transgenes, suitable regulatory elements, and elements required for producing viral proteins that mediate cell transduction. Such recombinant viruses can be produced by techniques known in the art, such as by transfecting packaging cells or by transient transfection with helper plasmids or viruses. Typical examples of viral packaging cells include (but are not limited to) HeLa cells, SF9 cells (optionally with baculovirus helper vectors), HEK293 cells, and the like. Herpes virus-based systems can be used to produce AAV vectors, as described in US20170218395A1. Detailed protocols for generating such replication-defective recombinant viruses can be found, for example, in WO95 / 14785, WO96 / 22378, U.S. Pat. No. 5,882,877, U.S. Pat. No. 6,013,516, U.S. Pat. No. 4,861,719, U.S. Pat. No. 5,278,056, and WO94 / 19478, the entire contents of each of which are incorporated herein by reference.
[0041] The present invention encompasses compositions and methods of use associated with B-cell lymphoma 2-associated immortality gene 3 (BAG3) proteins or polypeptides. In certain embodiments, the treated subject has one or more BAG3 gene mutations or downregulated BAG3 mRNA and / or protein expression or content. Mutations or downregulations in BAG3 that disrupt interaction with HSP70 are known to be associated with cardiomyopathy and heart failure, including diseases described in Fang et al. J Clin Invest. 127 (8): 3189-320 (2017) and Kieserman et al. J Am Heart Assoc. 8 (10) (2019) and other sources. Therefore, viral vector-mediated delivery of the BAG3 gene can be used as a viable therapeutic agent for BAG3-related human diseases (such as dilated cardiomyopathy and heart failure).
[0042] BAG3 gene mutations have been identified in people with BAG3-associated dilated cardiomyopathy (CMD1HH). (See "CMD1HH", NCBI MedGen). This condition is a hereditary heart disease characterized by dilation of the left ventricle or ventricular heart. Symptoms include dyspnea, syncope, fainting, fatigue, and chest pain. DCM can lead to death and can affect children and adults. In certain embodiments, BAG3 mutations include in-frame insertions of nucleotide variants compared to the wild-type BAG3 gene sequence. In certain embodiments, the in-frame insertion encodes an amino acid, such as a non-polar amino acid. In certain embodiments, the in-frame insertion comprises a 3-nucleotide insertion adding alanine at position 160.
[0043] In some embodiments, BAG3 comprises one or more amino acid substitutions. For example, BAG3 may have a C151R amino acid substitution numbered relative to SEQ ID NO: 1 (described in Villard, E. et al. Eur Heart J. 2011 May; 32(9): 1065-1076).
[0044] BAG3 may comprise one or more amino acid substitutions, insertions or deletions (collectively referred to as mutations) that alter BAG3 protein-protein binding interactions. For example, BAG3 C151R may increase interaction with actin-binding protein filamin A, hippo pathway kinase STK38, and E3 ubiquitin protein ligases DDB1 and TRIM21, while interaction with small heat shock protein HSPB7 and co-chaperone protein DNAJB1 may be reduced.
[0045] In some embodiments, the BAG3 protein comprises one or more amino acid substitutions at position C151 to a reference BAG3 protein.
[0046] In some embodiments, BAG3 comprises one or more amino acid modifications, such as substitutions, including but not limited to any of those disclosed in PCT Patent Application Publication No. WO2015117010A or No. WO2019237002A1, U.S. Patent No. 11,236,389, or U.S. Patent Application Publication No. US20180296703 or No. US20210254159, which are incorporated herein by reference in their entirety.
[0047] The polypeptide and polynucleotide coding sequences of human BAG3 are shown below: BAG3 - wild type (SEQ ID NO:1) - 575 amino acids MSAATHSPMMQVASGNGDRDPLPPGWEIKIDPQTGWPFFVDHNSRTTTWNDPRVPSEGPKETPSSANGPSR EGSRLPPAREGHPVYPQLRPGYIPIPVLHEGAENRQVHPFHVYPQPGMQRFRTEAAAAAPQRSQSPLRGMP ETTQPDKQCGQVAAAAAAQPPASHGPERSQSPAASDCSSSSSSASLPSSGRSSLGSHQLPRGYISIPVIHE QNVTRPAAQPSFHQAQKTHYPAQQGEYQTHQPVYHKIQGDDWEPRPLRAASPFRSSVQGASSREGSPARSS TPLHSPSPIRVHTVVDRPQQPMTHRETAPVSQPENKPESKPGPVGPELPPGHIPIQVIRKEVDSKPVSQKP PPPSEKVEVKVPPAPVPCPPPSPGPSAVPSSPKSVATEERAAPSTAPAEATPPKPGEAEAPPKHPGVLKVE AILEKVQGLEQAVDNFEGKKTDKKYLMIEEYLTKELLALDSVDPEGRADVRQARRDGVRKVQTILEKLEQK AIDVPGQVQVYELQPSNLEADQPLQAIMEMGAVAADKGKKNAGNAEDPHTETQQPEATAAATSNPSSMTDT PGNPAAP BAG3 - wild type (SEQ ID NO:2) - 1728 nucleotide bases
[0048] In some embodiments, the BAG3 protein comprises a polypeptide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 1. In some embodiments, the BAG3 protein comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 2. In some embodiments, the BAG3 protein is a wild-type or native BAG3 protein, such as human BAG3.
[0049] In some embodiments, the present invention provides a recombinant adeno-associated virus (rAAV) virus particle, comprising a capsid and a vector genome, wherein the vector genome comprises a polynucleotide sequence encoding BAG3 or a functional variant thereof operably linked to a promoter. In some embodiments, the present invention provides a recombinant adeno-associated virus (rAAV) virus particle, comprising a capsid and a vector genome, wherein the vector genome comprises a polynucleotide sequence encoding BAG3 operably linked to a promoter. The polynucleotide encoding BAG3 may comprise a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:2.
[0050] The AAV virus particles of the present invention comprise a vector genome. The vector genome may comprise an expression cassette (or a polynucleotide cassette for gene editing applications without the need for an expression polynucleotide sequence).
[0051] Optionally, the polynucleotide sequence encoding the vector genome may contain a Kozak sequence, including but not limited to GCCACCATGG (SEQ ID NO: 11). The Kozak sequence may overlap with the polynucleotide sequence encoding the BAG3 protein or a functional variant thereof.
[0052] In some embodiments, the Kozak sequence is a surrogate Kozak sequence comprising or consisting of any of the following: (gcc)gccRccAUGG(SEQ ID NO:13); AGNNAUGN; (SEQ ID NO: 45) ANNAUGG; (SEQ ID NO: 46) ANNAUGC; (SEQ ID NO: 47) ACCAUGG; (SEQ ID NO: 49), and GACACCAUGG (SEQ ID NO: 14), Or at least 80%, at least 85%, at least 90%, at least 95% or at least 98% identical to any one of SEQ ID NO: 13, 45, 46, 47, 49 or 14.
[0053] In some embodiments, the vector genome does not comprise a Kozak sequence.
[0054] The vector genome may include 5' and / or 3' inverted terminal repeats (ITRs). Any suitable ITR can be used. ITR may be an AAV ITR from the same serotype as the capsid present in the AAV virion or a serotype different from the capsid (e.g., AAV2 ITR can be used with an AAV virion having an AAV9 capsid or an AAVrh74 capsid). In various cases, the serotype of the capsid determines the name applicable to the virion. ITR is generally most of the 5' and most of the 3' elements in the vector genome. The vector genome will also generally contain a promoter, a transgene, a 3' untranslated region (UTR) sequence (e.g., a WPRE element), and a polyadenylation sequence in a 5' to 3' order. In a variant form, the vector genome includes an enhancer element (generally at the 5' of the promoter) and / or an exon (generally at the 3' of the promoter). In a variant form, the vector genome includes a green fluorescent protein (GFP) protein, generally at the 3' of the transgene. In a variant form, the vector genome of the present invention encodes a partial or complete transgenic sequence used as a repair template in a gene editing system. In such variations, the vector genome can contain an exogenous promoter, or the gene editing system can insert the transgene into a locus in the genome that has an endogenous promoter, such as a cardiac muscle or myocyte-specific promoter.
[0055] In some embodiments, the 5' ITR comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:15. SEQ ID NO:15
[0056] In some embodiments, the 5' ITR comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:16. SEQ ID NO:16
[0057] In some embodiments, the 5' ITR comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:17. SEQ ID NO:17
[0058] In some embodiments, the 5' ITR comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:18. SEQ ID NO:18
[0059] In some embodiments, the 3' ITR comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:19. SEQ ID NO:19
[0060] In some embodiments, the 3' ITR comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:20. SEQ ID NO:20
[0061] In some embodiments, the 3' ITR comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:21. SEQ ID NO:21
[0062] In some embodiments, the vector genome comprises one or more stuffer sequences that are, for example, at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24. SEQ ID NO:22 SEQ ID NO:23 SEQ ID NO:24
[0063] In some embodiments, the polynucleotide sequence encoding the BAG3 protein or its functional variant is operably linked to a promoter. In some embodiments, the promoter is the MHCK7 promoter. In some embodiments, the promoter is the TNNT2 promoter. In some embodiments, the promoter is the HSP70 promoter. In some embodiments, the promoter is the UBC promoter. In some embodiments, the promoter is the CAG promoter or the chicken β-actin promoter.
[0064] The present invention encompasses the use of various promoters. Promoters suitable for use in embodiments of the present invention include, but are not limited to, a cytomegalovirus (CMV) promoter, a phosphoglycerate kinase (PGK) promoter, or a promoter sequence comprising a CMV enhancer and a portion of a chicken β-actin promoter and a rabbit β-globin gene (CAG). In some cases, the promoter may be a synthetic promoter. Exemplary synthetic promoters are provided by Schlabach et al. PNAS USA. 107 (6): 2538–43 (2010). In some embodiments, the promoter comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 25. SEQ ID NO:25.
[0065] In some embodiments, the polynucleotide sequence encoding BAG3 protein or its functional variant is operably connected to an inducible promoter. Inducible promoters can be configured to make the polynucleotide sequence transcribed or not transcribed in response to adding or accumulating reagents or in response to removing, degrading or diluting reagents. Reagents can be drugs. Reagents can be one of tetracycline or its derivatives, including, but not limited to, doxycycline. In some cases, inducible promoters are tet-on promoters, tet-off promoters, chemically regulated promoters, physically regulated promoters (i.e., promoters that are responsive to the presence or absence of light or to low or high temperatures). Inducible promoters include heavy metal ion inducible promoters (such as mouse mammary tumor virus (mMTV) promoters or various growth hormone promoters), and promoters active in the presence of T7 RNA polymerase from T7 bacteriophages. This list of inducible promoters is non-restrictive.
[0066] In some cases, the promoter is a tissue-specific promoter, such as a promoter capable of driving expression in cardiac cells to a higher degree than in non-cardiac cells. In some embodiments, the tissue-specific promoter is selected from any of various myocardial tissue or cell-specific promoters, including but not limited to desmin (Des), α-myosin heavy chain (α-MHC), myosin light chain 2 (MLC-2), cardiac troponin C (cTnC), cardiac troponin T (hTNNT2), muscle creatine kinase (CK) and a combination of promoter / enhancer regions thereof, such as MHCK7. In some embodiments, the promoter is inducible by environmental stimuli. In some embodiments, the promoter is a heat shock protein 70 (HSP70) promoter. In some cases, the promoter is a ubiquitin promoter. "Ubiquitin promoter" refers to a promoter that is not tissue-specific under experimental or clinical conditions. In some cases, the ubiquitin promoter is any one of: cytomegalovirus (CMV), a cytomegalovirus early enhancer element, a chicken β-actin gene intron with a splice acceptor of the rabbit β-globin gene (CAG), ubiquitin C (UBC), phosphoglycerate kinase (PGK), eukaryotic translation elongation factor 1 alpha 1 (EF1-α), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), simian virus 40 (SV40), hepatitis B virus (HBV), chicken β-actin, and human β-actin promoter.
[0067] In some embodiments, the promoter sequence is selected from Table 1. In some embodiments, the promoter comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 31 to 48, 115 or 116. In some embodiments, the promoter comprises a fragment of a polynucleotide sequence of any one of SEQ ID NOs: 31 to 48, such as a fragment comprising at least 25%, at least 50%, at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of any one of SEQ ID NOs: 31 to 51, 115 or 116. For example, in some embodiments, the promoter is a fragment of the UBC promoter consisting of about the first 400 nucleotides of the UBC promoter sequence of SEQ ID NO: 116. Table 1
[0068] In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 31. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 32. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 33. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 34. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 35. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 36. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 37. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 38. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 39. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:40.In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 41. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 42. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 43. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 44. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 48. In a certain embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 115. In one embodiment, the vector genome comprises a polynucleotide sequence that is at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:116.
[0069] Other illustrative examples of promoters are the SV40 late promoter from simian virus 40, the baculovirus polyhedral enhancer / promoter element, herpes simplex virus thymidine kinase (HSV tk), the immediate early promoter from cytomegalovirus (CMV), and various retroviral promoters, including LTR elements. A variety of other promoters are known and generally available in the art, and the sequences of many such promoters are available in sequence databases such as the GenBank database.
[0070] In some cases, the vectors of the invention further comprise one or more regulatory elements selected from the group consisting of an enhancer, an intron, a polyadenylation signal, a 2A peptide coding sequence, a WPRE (woodchuck hepatitis virus posttranscriptional regulatory element) and a HPRE (hepatitis B posttranscriptional regulatory element). In certain embodiments, the vector comprises a mutant or modified WPRE (collectively referred to as WPRE (x), such as a WPRE disclosed in any one of SEQ ID NOs: 62 to 67 or 70, or a mutant or modified WPRE, optionally a modified WPRE disclosed in SEQ ID NO: 63 (WPRE Mut6; see Zanta-Boussif, M., Charrier, S., Brice-Ouzet, A. et al. Validation of a mutated PREsequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther 16, 605–619 (2009). https: / / doi.org / 10.1038 / gt.2009.3). In a specific embodiment, the modified WPRE comprises a start codon that modifies the WHV-X protein, thereby preventing its expression.
[0071] In some embodiments, the vector comprises a CMV enhancer.
[0072] In certain embodiments, the vector comprises one or more enhancers. In a specific embodiment, the enhancer is a CMV enhancer sequence, a GAPDH enhancer sequence, a β-actin enhancer sequence, or an EF1-α enhancer sequence. The aforementioned sequences are known in the art. For example, the sequence of the CMV immediate early (IE) enhancer is SEQ ID NO: 50. SEQ ID NO: 50 acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat 60 aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga 120 gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc 180 ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt 240 atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta cca 293
[0073] In certain embodiments, the vector comprises one or more introns. In specific embodiments, the intron is a rabbit globin intron sequence, a chicken β-actin intron sequence, a synthetic intron sequence, an SV40 intron, or an EF1-α intron sequence.
[0074] In certain embodiments, the vector comprises a polyadenylic acid sequence. In specific embodiments, the polyadenylic acid sequence is a rabbit globulin polyadenylic acid sequence, a human growth hormone polyadenylic acid sequence, a bovine growth hormone polyadenylic acid sequence, a PGK polyadenylic acid sequence, an SV40 polyadenylic acid sequence, or a TK polyadenylic acid sequence. In some embodiments, the polyadenylic acid signal may be a bovine growth hormone polyadenylation signal (bGHpA).
[0075] In certain embodiments, the vector comprises one or more transcript stabilizing elements. In specific embodiments, the transcript stabilizing element is a WPRE sequence, an HPRE sequence, a scaffold junction, a 3'UTR or a 5'UTR. In specific embodiments, the vector comprises a 5'UTR and a 3'UTR.
[0076] In some embodiments, the vector comprises a 5' untranslated region (UTR) selected from Table 2. In some embodiments, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs 51 to 61. Table 2
[0077] In some embodiments, the vector comprises a 3' untranslated region selected from Table 5. In some embodiments, the vector genome comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs 62 to 70. Table 3
[0078] In some embodiments, the vector comprises a polyadenylation (poly(A)) signal selected from Table 4. In some embodiments, the poly(A) signal comprises a polynucleotide sequence at least 75%, 80%, 85%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs 71 to 75. Table 4
[0079] An illustrative vector genome is depicted in Figures 1 to 8 and are provided as SEQ ID NOs: 107 to 114. In some embodiments, the vector genome comprises, consists essentially of, or consists of a polynucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 26 to 30 and 76 to 95, optionally with or without ITR sequences.
[0080] In a certain embodiment, the vector genome comprises, in 5′ to 3′ order, a 5′ ITR, a MHCK7 promoter, an SV-40 chimeric intron, a BAG3 transgene, a WPRE(x) element, a human GH polyadenylation signal (hGH) sequence, and a 3′ ITR. The vector genome may comprise, in 5′ to 3′ order, a polynucleotide sequence of SEQ ID NO: 107 or a polynucleotide sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to each of the foregoing items. In certain embodiments, the vector genome is encapsulated in an AAV9 or AAVrh74 vector. In certain embodiments, the vector genome is encapsulated in an AAVrh74 vector. SEQ ID NO:107
[0081] In a certain embodiment, the vector genome comprises a 5'ITR, an hTNNT2 promoter, a BAG3 transgene, a WPRE(x) element, a human GH polyadenylation signal (hGH) sequence, and a 3'ITR in a 5' to 3' order. The vector genome may comprise a polynucleotide sequence of SEQ ID NO: 108 or a polynucleotide sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to each of the foregoing items in a 5' to 3' order. In certain embodiments, the vector genome is encapsulated in an AAV9 or AAVrh74 vector. In certain embodiments, the vector genome is encapsulated in an AAVrh74 vector. SEQ ID NO:108
[0082] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR, an HSP70 promoter, a BAG3 transgene, a WPRE (x) element, a human GH polyadenylation signal (hGH) sequence, and a 3' ITR. The vector genome may comprise, in 5' to 3' order, a polynucleotide sequence of SEQ ID NO: 109 or a polynucleotide sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to each of the foregoing items. In certain embodiments, the vector genome is encapsulated in an AAV9 or AAVrh74 vector. In certain embodiments, the vector genome is encapsulated in an AAVrh74 vector. SEQ ID NO:109
[0083] In a certain embodiment, the vector genome comprises, in 5′ to 3′ order, a 5′ ITR, a MHCK7 promoter, an SV-40 chimeric intron, a BAG3 transgene, an enhanced green fluorescent protein (eGFP), a WPRE(x) element, a human GH polyadenylation signal (hGH) sequence, and a 3′ ITR. The vector genome may comprise, in 5′ to 3′ order, a polynucleotide sequence of SEQ ID NO: 110 or a polynucleotide sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to each of the foregoing items. In certain embodiments, the vector genome is encapsulated in an AAV9 or AAVrh74 vector. In certain embodiments, the vector genome is encapsulated in an AAVrh74 vector. SEQ ID NO:110 ttggccactccctctctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcc tcagtgagcgagcgagcgcgcagagaggggagtggccaactccatcactaggggttcctcctgaggacgcgtacccttcagattaaaa ataactgaggtaagggcctgggtaggggaggtggtgtgagacgctcctgtctctcctctatctgcccatcggccctttggggaggag gaatgtgcccaaggactaaaaaaaggccatggagccagaggggcgagggcaacagacctttcatgggcaaaccttggggccctgctg tctagcatgccccactacgggtctaggctgcccatgtaaggaggcaaggcctggggacacccgagatgcctggttataattaaccca gacatgtggctgcccccccccccccaacacctgctgcctctaaaaataaccctgtccctggtggatcccctgcatgcgaagatcttc gaacaaggctgtgggggactgagggcaggctgtaacaggcttgggggccagggcttatacgtgcctgggactcccaaagtattactg ttccatgttcccggcgaagggccagctgtcccccgccagctagactcagcacttagtttaggaaccagtgagcaagtcagcccttgg ggcagcccatacaaggccatggggctgggcaagctgcacgcctgggtccggggtgggcacggtgcccgggcaacgagctgaaagctc atctgctctcaggggcccctccctggggacagcccctcctggctagtcacaccctgtaggctcctctatataacccaggggcacagg ggctgccctcattctaccaccacctccacagcacagacagacactcaggagccagccagggtaagtttagtctttttgtcttttatt tcaggtcccggatccggtggtggtgcaaatcaaagaactgctcctcagtggatgttgcctttacttctaggcctgtacggaagtgtt acttctgctctaaaagctgcggaattgtacccgcgccaccATGagcgccgccacccactcgcccatgatgcaggtggcgtccggcaa cggtgaccgcgaccctttgccccccggatgggagatcaagatcgacccgcagaccggctggcccttcttcgtggaccacaacagccg caccactacgtggaacgacccgcgcgtgccctctgagggccccaaggagactccatcctctgccaatggcccttcccgggagggctc taggctgccgcctgctagggaaggccaccctgtgtacccccagctccgaccaggctacattcccattcctgtgctccatgaaggcgc tgagaaccggcaggtgcaccctttccatgtctatccccagcctgggatgcagcgattccgaactgaggcggcagcagcggctcctca gaggtcccagtcacctctgcggggcatgccagaaaccactcagccagataaacagtgtggacaggtggcagcggcggcggcagccca gcccccagcctcccacggacctgagcggtcccagtctccagctgcctctgactgctcatcctcatcctcctcggccagcctgccttc ctccggcaggagcagcctgggcagtcaccagctcccgcgggggtacatctccattccggtgatacacgagcagaacgttacccggcc agcagcccagccctccttccaccaagcccagaagacgcactacccagcgcagcagggggagtaccagacccaccagcctgtgtacca caagatccagggggatgactgggagccccggcccctgcgggcggcatccccgttcaggtcatctgtccagggtgcatcgagccggga gggctcaccagccaggagcagcacgccactccactccccctcgcccatccgtgtgcacaccgtggtcgacaggcctcagcagcccat gacccatcgagaaactgcacctgtttcccagcctgaaaacaaaccagaaagtaagccaggcccagttggaccagaactccctcctgg acacatcccaattcaagtgatccgcaaagaggtggattctaaacctgtttcccagaagcccccacctccctctgagaaggtagaggt gaaagttccccctgctccagttccttgtcctcctcccagccctggcccttctgctgtcccctcttcccccaagagtgtggctacaga agagagggcagcccccagcactgcccctgcagaagctacacctccaaaaccaggagaagccgaggctcccccaaaacatccaggagt gctgaaagtggaagccatcctggagaaggtacaggggctggagcaggctgtagacaactttgaaggcaagaagactgacaaaaagta cctgatgatcgaagagtatttgaccaaagagctgctggccctggattcagtggaccccgagggacgagccgatgtgcgtcaggccag gagagacggtgtcaggaaggttcagaccatcttggaaaaacttgaacagaaagccattgatgtcccaggtcaagtccaggtctatga actccagcccagcaaccttgaagcagatcagccactgcaggcaatcatggagatgggtgccgtggcagcagacaagggcaagaaaaa tgctggaaatgcagaagatccccacacagaaacccagcagccagaagccacagcagcagcgacttcaaaccccagcagcatgacaga cacccctggtaacccagcagcaccg ggatccggcagtggagagggcagaggaagtctgctaacatgcg gtgacgtcgaggagaatcc tggcccaATGAGCAAGGGCGAGGAGCTGTTCACCGGCGTGGTGCCCATCCTGGTGGAGCTGGACGGCG ACGTGAACGGCCACAAGTT CAGCGTGAGAGGCGAGGGCGAGGGCGACGCCACCAACGGCAAGCTGACCCTGAAGTTCATCTGCACCAC CGGCAAGCTGCCCGTGCC CTGGCCCACCCTGGTGACCACCCTGACCTACGGCGTGCTGTGCTTCAGCAGATACCCCGACCACATGAA GAGACACGACTTCTTCAA GAGCGCCATGCCCGAGGGCTACGTGCAGGAGAGAACCATCAGCTTCAAGGACGACGGCACCTACAAGAC CAGAGCCGAGGTGAAGTT CGAGGGCGACACCCTGGTGAACAGAATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCT GGGCCACAAGCTGGAGTA CAACTTCAACAGCCACAACGTGTACATCACCGCCGACAAGCAGAAGAACGGCATCAAGGCCTACTTCAA GATCAGACACAACGTGGA GGACGGCAGCGTGCAGCTGGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCT GCCCGACAACCACTACCT GAGCACCCAGAGCGTGCTGAGCAAGGACCCCAACGAGAAGAGAGACCACATGGTGCTGCTGGAGGACGT GACCGCCGCCGGCATCAC CCACGGCATGGACGAGCTGTACAAGTGAtcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctc cttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtata aatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaaccc ccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcg ccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttc cttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttc cttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcct ccccgcactgcccgggtggcatccctgtgacccctccccagtgcctctcctggccctggaagttgccactccagtgcccaccagcct tgtcctaataaaattaagttgcatcattttgtctgactaggtgtccttctataatattatggggtggaggggggtggtatggagcaa ggggcccaagttgggaagaaacctgtagggcctgccctaaggaggaacccctagtgatggagttggccactccctctctgcgcgctc gctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagag agggagtggccaa
[0084] In a certain embodiment, the vector genome comprises, in 5′ to 3′ order, a 5′ ITR, a TNNT2 promoter, a BAG3 transgene, an enhanced green fluorescent protein (eGFP), a WPRE(x) element, a human GH polyadenylation signal (hGH) sequence, and a 3′ ITR. The vector genome may comprise, in 5′ to 3′ order, a polynucleotide sequence of SEQ ID NO: 111 or a polynucleotide sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to each of the foregoing items. In certain embodiments, the vector genome is encapsulated in an AAV9 or AAVrh74 vector. In certain embodiments, the vector genome is encapsulated in an AAVrh74 vector.
[0085] SEQ ID NO:111
[0086] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR, an HSP70 promoter, a BAG3 transgene, an enhanced green fluorescent protein (eGFP), a WPRE (x) element, a human GH polyadenylation signal (hGH) sequence, and a 3' ITR. The vector genome may comprise, in 5' to 3' order, a polynucleotide sequence of SEQ ID NO: 112 or a polynucleotide sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to each of the foregoing items. In certain embodiments, the vector genome is encapsulated in an AAV9 or AAVrh74 vector. In certain embodiments, the vector genome is encapsulated in an AAVrh74 vector. SEQ ID NO:112
[0087] In a certain embodiment, the vector genome comprises, in 5′ to 3′ order, a 5′ ITR, a CMV promoter, a chicken β-actin promoter, a chimeric intron, a BAG3 transgene, an enhanced green fluorescent protein (eGFP), a WPRE(x) element, a human GH polyadenylation signal (hGH) sequence, and a 3′ ITR. The vector genome may comprise, in 5′ to 3′ order, a polynucleotide sequence of SEQ ID NO: 113 or a polynucleotide sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to each of the foregoing items. In certain embodiments, the vector genome is encapsulated in an AAV9 or AAVrh74 vector. In certain embodiments, the vector genome is encapsulated in an AAVrh74 vector. SEQ ID NO:113
[0088] In a certain embodiment, the vector genome comprises, in 5' to 3' order, a 5' ITR, a UBC promoter, a BAG3 transgene, a WPRE(x) element, a human GH polyadenylation signal (hGH) sequence, and a 3' ITR. The vector genome may comprise, in 5' to 3' order, a polynucleotide sequence of SEQ ID NO: 114 or a polynucleotide sequence having 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to each of the foregoing items. In certain embodiments, the vector genome is encapsulated in an AAV9 or AAVrh74 vector. In certain embodiments, the vector genome is encapsulated in an AAVrh74 vector. SEQ ID NO:114 ttggccactccctctctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggt cgcccggcctcagtgagcgagcgagcgcgcagagaggggagtggccaactccatcactaggggttcctcctgaggacgc gtgatctggcctccgcgccgggttttggcgcctcccgcgggcgcccccctcctcacggcgagcgctgccacgtcagac gaagggcgcaggagcgtcctgatccttccgcccggacgctcaggacagcggcccgctgctcataagactcggccttag aaccccagtatcagcagaaggacattttaggacgggacttgggtgactctagggcactggttttctttccagagagcg gaacaggcgaggaaaagtagtcccttctcggcgattctgcggagggatctccgtggggcggtgaacgccgatgattat ataaggacgcgccgggtgtggcacagctagttccgtcgcagccgggatttgggtcgcggttcttgtttgtggatcgct gtgatcgtcacttggtgagtagcgggctgctgggctggccggggctttcgtggccgccgggccgctcggtgggacgga agcgtgtggagagaccgccaagggctgtagtctgggtccgcgagcaaggttgccctgaactgggggttggggggagcg cagcaaaatggcggctgttcccgagtcttgaatggaagacgcttgtgaggcgggctgtgaggtcgttgaaacaaggtg gggggcatggtgggcggcaagaacccaaggtcttgaggccttcgctaatgcgggaaagctcttattcgggtgagatgg gctggggcaccatctggggaccctgacgtgaagtttgtcactgactggagaactcggtttgtcgtctgttgcgggggc ggcagttatgcggtgccgttgggcagtgcacccgtacctttgggagcgcgcgccctcgtcgtgtcgtgacgtcacccg ttctgttggcttataatgcagggtggggccacctgccggtaggtgtgcggtaggcttttctccgtcgcaggacgcagg gttcgggcctagggtaggctctcctgaatcgacaggcgccggacctctggtgaggggagggataagtgaggcgtcagt ttctttggtcggttttatgtacctatcttcttaagtagctgaagctccggttttgaactatgcgctcggggttggcga gtgtgttttgtgaagtttttaggcaccttttgaaatgtaatcatttgggtcaatatgtaattttcagtgttagacta gtaaattgtccgctaaattctggccgtttttggcttttttgttagacgaaggccaccATGagcgccgccaccaccactcg cccatgatgcaggtggcgtccggcaacggtgaccgcgaccctttgccccccggatgggagatcaagatcgacccgcag accggctggcccttcttcgtggaccacaacagccgcaccactacgtggaacgacccgcgcgtgccctctgagggcccc aaggaactccatcctctgccaatggcccttcccgggagggctctaggctgccgcctgctagggaaggccaccctgtg tacccccagctccgaccaggctacattcccattcctgtgctccatgaaggcgctgagaaccggcaggtgcaccctttc catgtctatccccagcctgggatgcagcgattccgaactgaggcggcagcagcggctcctcagaggtcccagtcacct ctgcggggcatgccagaaaccactcagccagataaacagtgtggacaggtggcagcggcggcggcagcccagccccca gcctcccacggacctgagcggtcccagtctccagctgccctctgactgctcatcctcatcctcctcggccagcctgcct tcctccggcaggagcagcctgggcagtcaccagctcccgcgggggtacatctccattccggtgatacacgagcagaac gttacccggccagcagcccagccctccttccaccaagcccagaagacgcactacccagcgcagcagggggagtaccag acccaccagcctgtgtaccacaagatccagggggatgactgggagccccggcccctgcgggcggcatccccgttcagg tcatctgtccagggtgcatcgagccgggagggctcaccagccaggagcagcacgccactccactccccctcgcccatc cgtgtgcacaccgtggtcgacaggcctcagcagcccatgacccatcgagaaactgcacctgtttcccagcctgaaaac aaaccagaaagtaagccaggcccagttggaccagaactccctcctggacacatcccaattcaagtgatccgcaaagag gtggattctaaacctgtttcccagaagcccccacctccctctgagaaggtagaggtgaaagttccccctgctccagtt ccttgtcctcctcccagccctggcccttctgctgtcccctcttcccccaagagtgtggctacagaagagagggcagcc cccagcactgcccctgcagaagctacacctccaaaaccaggagaagccgaggctcccccaaaacatccaggagtgctg aaagtggaagccatcctggagaaggtacaggggctggagcaggctgtagacaactttgaaggcaagaagactgacaaa aagtacctgatgatcgaagagtatttgaccaaagagctgctggccctggattcagtggaccccgagggacgagccgat gtgcgtcaggccaggagagacggtgtcaggaaggttcagaccatcttggaaaaacttgaacagaaagccattgatgtc ccaggtcaagtccaggtctatgaactccagcccagcaaccttgaagcagatcagccactgcaggcaatcatggagatg ggtgccgtggcagcagacaagggcaagaaaaatgctggaaatgcagaagatccccacacagaaacccagcagccagaa gccacagcagcagcgacttcaaaccccagcagcatgacagacacccctggtaacccagcagcaccgTAGtcaacctct ggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgcttt aatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctct ttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttg gggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgc cgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatc gtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccct caatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagac gagtcggatctccctttgggccgcctccccgcactgcccgggtggcatccctgtgacccctccccagtgcctctcctg gccctggaagttgccactccagtgcccaccagccttgtcctaataaaattaagttgcatcattttgtctgactaggtg tccttctataatattatggggtggaggggggtggtatggagcaaggggcccaagttgggaagaaacctgtagggcctg ccctaaggaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgacc aaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagaggggagtggccaa
[0089] In each case, the WPRE element may optionally be present or absent. Adeno-associated virus vector
[0090] AAV vectors suitable for practicing the present invention can be packaged into AAV virions (viral particles) using a variety of systems, including adenovirus-based and helper virus-free systems. Standard methods in AAV biology include those described in Kwon and Schaffer. Pharm Res. (2008) 25(3):489-99; Wu et al. Mol. Ther. (2006) 14(3):316-27. Burger et al. Mol. Ther. (2004) 10(2):302-17; Grimm et al. Curr Gene Ther. (2003) 3(4):281-304; Deyle DR, Russell DW. Curr Opin Mol Ther. (2009) 11(4):442-447; McCarty et al. Gene Ther. (2001) 8(16):1248-54; and Duan et al. Mol Ther. (2001) 4(4):383-91. Helper cell-free systems include those described in US 6,004,797, US 7,588,772 and US 7,094,604.
[0091] The AAV DNA in the rAAV genome can be derived from any AAV variant or serotype from which recombinant viruses can be derived, including, but not limited to, AAV variants or serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, AAV-13, AAVrh.74, and AAVrh10. The production of pseudotyped rAAVs is disclosed, for example, in WO01 / 83692. Other types of rAAV variants, such as rAAVs with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). The nucleotide sequences of the genomes of various AAV serotypes are known in the art.
[0092] In some cases, rAAV includes a self-complementary genome. As defined herein, rAAV comprising a "self-complementary" or "double-stranded" genome refers to an rAAV that has been engineered so that the coding region of rAAV is constructed to form an intramolecular double-stranded DNA template, such as McCarty et al. Self-complementary recombinant adeno-associated virus (scAAV) vectors promoter efficient transduction independently of DNA synthesis. Gene Therapy. 8 (16): described in 1248–54 (2001). In some cases, the present invention encompasses the use of rAAVs including self-complementary genomes, because when infecting (such transduction) rather than waiting for the cell-mediated synthesis of the second chain of the rAAV genome, the two complementary halves of scAAV will associate to form a double-stranded DNA (dsDNA) unit ready to be replicated and transcribed immediately. It should be understood that instead of the full coding capacity found in rAAV (4.7 to 6 kb), rAAVs comprising self-complementary genomes can only maintain about half of this amount (≈2.4 kb).
[0093] In other cases, the rAAV vector comprises a single-stranded genome. As defined herein, a "single-stranded" genome refers to a non-self-complementary genome. In most cases, non-recombinant AAV has a single-stranded DNA genome. There are some indications that rAAV should be scAAV to achieve efficient transduction of cells. However, the present invention encompasses rAAV vectors that may have a single-stranded genome rather than a self-complementary genome, and it should be understood that other genetic modifications of rAAV vectors may be beneficial for obtaining optimal gene transcription in target cells.
[0094] In some cases, the rAAV vector has a serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh10 or AAVrh74. The production of pseudotyped rAAVs is disclosed in, for example, WO 01 / 83692. Other types of rAAV variants, such as rAAVs with capsid mutations, are also contemplated. See, for example, Marsic et al., Molecular Therapy, 22(11): 1900-1909 (2014). In certain embodiments, the rAAV vector has a serotype AAVrh74. In some cases, the rAAV vector has a serotype AAV9. In some embodiments, the rAAV vector has a serotype AAV9 and comprises a single-stranded genome. In some embodiments, the rAAV vector has a serotype AAV9 and comprises a self-complementary genome. In some embodiments, the rAAV vector comprises an inverted terminal repeat (ITR) sequence of AAV2. In some embodiments, the rAAV vector comprises an AAV2 genome, such that the rAAV vector is an AAV-2 / 9 vector, an AAV-2 / 6 vector, or an AAV-2 / 8 vector.
[0095] The full length sequences and sequences of the capsid genes of most known AAVs are provided in U.S. Patent No. 8,524,446, which is incorporated herein in its entirety.
[0096] The AAV vector may comprise a wild-type AAV sequence or it may comprise one or more modifications to a wild-type AAV sequence. In certain embodiments, the AAV vector comprises one or more amino acid modifications, optionally substitutions, deletions or insertions, within the capsid protein (optionally VP1, VP2 and / or VP3). In specific embodiments, when the AAV vector is provided to a subject, the modification reduces immunogenicity.
[0097] The capsid protein of rAAV can be modified to target rAAV to a specific target tissue of interest, such as cardiomyocytes. In some embodiments, rAAV is injected directly into the intraventricular space of a subject.
[0098] In some embodiments, the rAAV virion is an AAVrh.74rAAV virion. The capsid may be an AAVrh.74 capsid or a functional variant thereof. In some embodiments, the AAVrh.74 capsid is at least 98%, 99% or 100% identical to a reference AAVrh.74 capsid (e.g., SEQ ID NO: 100). In a specific embodiment, the rAAVrh.74rAAV virion candidate targets adults with DCM and has greater safety and / or efficacy than other AAV serotypes.
[0099] In some embodiments, the rAAV virion is an AAV2 rAAV virion. The capsid may be an AAV2 capsid or a functional variant thereof. In some embodiments, the AAV2 capsid is at least 98%, 99% or 100% identical to a reference AAV2 capsid (eg, SEQ ID NO: 96). SEQ ID NO:96
[0100] In some embodiments, the rAAV virion is an AAV9 rAAV virion. The capsid may be an AAV9 capsid or a functional variant thereof. In some embodiments, the AAV9 capsid is at least 98%, 99% or 100% identical to a reference AAV9 capsid (eg, SEQ ID NO: 97). SEQ ID NO:97
[0101] In some embodiments, the rAAV virion is an AAV6 rAAV virion. The capsid may be an AAV6 capsid or a functional variant thereof. In some embodiments, the AAV6 capsid is at least 98%, 99% or 100% identical to a reference AAV6 capsid (eg, SEQ ID NO: 98). SEQ ID NO:98
[0102] In some embodiments, the rAAV virion is an AAVrh.10 rAAV virion. The capsid may be an AAVrh.10 capsid or a functional variant thereof. In some embodiments, the AAVrh.10 capsid is at least 98%, 99% or 100% identical to a reference AAVrh.10 capsid (eg, SEQ ID NO: 99). SEQ ID NO:99
[0103] In some embodiments, the capsid protein is encoded by a polynucleotide provided in trans on a plasmid to a transfer plasmid.The polynucleotide sequence of wild-type AAVrh74cap is provided as SEQ ID NO:100. SEQ ID NO:100
[0104] The present invention further provides the protein sequences of AAVrh74 VP1, VP2 and VP3, including SEQ ID NO: 101 to 103, and their homologs or functional variants. SEQ ID NO:101 MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDNGRGLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKA YDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQAKKRVLEPLGLVESPVKTAPGKKRPVEPSPQRSPDS STGIGKKGQQPAKKRLNFGQTGDSESVPDPQPIGEPPAGPSGLGSGTMAAGGGAPMADNNEGADGVGSSSGNWHCDST WLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPK RLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAV GRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLFSQA GPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEERFFPSSGVLMFG KQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNAAPIVGAVNSQGALPGMVWQNRDVYLQGPIWAKI PHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQAKLASFITQYSTGQVSVEIEWELQKENSKRWNPEIQ YTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLTRNL SEQ ID NO:102 TAPGKKRPVEPSPQRSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVPDPQPIGEPPAGPSGLGSGTMAAGGGAPMADN NEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCH FSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPAD VFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLS RTQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMA THKDDEERFFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNAAPIVGAVNSQGALP GMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQAKLASFITQYSTGQVSV EIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLTRL SEQ ID NO:103 MAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNHLYKQISNGTSGGSTNDNTYFGYSTP WGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGS AHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDRLM NPLIDQYLYYLSRTQSTGGTAGTQQLLFSQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNG RDSLVNPGVAMATHKDDEERFFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNAAP IVGAVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPPTTFNQAKLAS FITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGTRYLTRNL
[0105] In some cases, the AAVrh74 capsid comprises the amino acid sequence shown in SEQ ID NO: 101. In some embodiments, the rAAV vector comprises a polypeptide comprising, consisting essentially of, or further consisting of, for example, a sequence having at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more usually 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to the amino acid sequence of AAVrh74 VP1 shown in SEQ ID NO: 101. In some embodiments, the rAAV vector comprises a polypeptide comprising, consisting essentially of, or further consisting of a sequence having, for example, at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more usually 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to the amino acid sequence of AAVrh74 VP2 shown in SEQ ID NO:102. In some embodiments, the rAAV vector comprises a polypeptide comprising, consisting essentially of, or further consisting of a sequence having, for example, at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more usually 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identity to the amino acid sequence of AAVrh74 VP3 shown in SEQ ID NO:103.
[0106] In some embodiments, the rAAV virion is an AAV-PHP.B rAAV virion or a neurotrophic variant thereof, such as, but not limited to, variants disclosed in International Patent Publication Nos. WO 2015 / 038958 A1 and WO 2017 / 100671 A1. For example, the AAV capsid may comprise at least 4 consecutive amino acids from the sequence TLAVPFK (SEQ ID NO: 105) or KFPVALT (SEQ ID NO: 106), for example, inserted between the sequence encoding amino acids 588 and 589 of AAV9.
[0107] The capsid may be an AAV-PHP.B capsid or a functional variant thereof. In some embodiments, the AAV-PHP.B capsid is at least 98%, 99% or 100% identical to a reference AAV-PHP.B capsid (eg, SEQ ID NO: 104). SEQ ID NO:104
[0108] Other AAV capsids used in the rAAV virions of the present invention include those described in Patent Publication Nos. WO 2009 / 012176 A2 and WO 2015 / 168666 A2.
[0109] Without being bound by theory, the inventors have determined that AAVrh.74, AAV9 vectors, or AAVrh.10 vectors will confer the desired cardiac tropism to the vector. Without being bound by theory, the inventors have further determined that AAVrh.74, AAV9 vectors, or AAVrh.10 vectors can provide the desired specificity to cardiac cells.
[0110] In one aspect, the invention provides a pharmaceutical composition comprising a rAAV virion of the invention and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0111] For the purpose of optionally administering by injection, various solutions, such as sterile aqueous solutions, can be used. If necessary, such aqueous solutions can be buffered, and the liquid diluent is first made isotonic with physiological saline or glucose. It can be suitably mixed with surfactants such as poloxamer (Poloxamer) 188 in water with, for example, 0.001% or 0.01% to prepare a solution of rAAV as a free acid (DNA contains an acidic phosphate group) or a pharmacologically acceptable salt. Dispersions of rAAV can also be prepared in glycerol, liquid polyethylene glycol and mixtures thereof, and in oil. Under general storage and use conditions, these preparations contain preservatives to prevent microbial growth. In this regard, the sterile aqueous medium used can be easily obtained by standard techniques known to those skilled in the art.
[0112] The pharmaceutical form suitable for injectable use includes, but is not limited to, sterile aqueous solutions or dispersions and sterile powders for the temporary preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that there is easy injectability. It must be stable under manufacturing and storage conditions, and must prevent the contamination of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (such as glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. Appropriate fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using a surfactant. The prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In most cases, it preferably includes an isotonic agent, such as sugar or sodium chloride. The absorption extension of the injectable pharmaceutical composition can be achieved by using an agent that delays absorption, such as aluminum monostearate and gelatin.
[0113] Sterile injectable solutions are prepared by incorporating the required amount of rAAV in an appropriate solvent along with the various other ingredients listed above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle containing a basic dispersion medium and the required other ingredients from the ingredients listed above. In the case of sterile powders for the preparation of sterile injectable solutions, certain methods of preparation are vacuum drying and freeze drying techniques that produce a powder of the active ingredient plus any additional desired ingredients, starting from a previously sterile filtered solution thereof.
[0114] In another aspect, the invention comprises a kit comprising the rAAV virion of the invention and instructions for use.
[0115] In one aspect, the disclosure provides a method for increasing BAG3 activity in a cell, comprising contacting the cell with an rAAV of the disclosure. In another aspect, the disclosure provides a method for increasing BAG3 activity in a subject, comprising administering an rAAV of the disclosure to the subject. In some embodiments, the cell and / or subject lacks BAG3 messenger RNA or BAG3 protein expression and / or activity, and / or comprises a loss-of-function mutation in BAG3. In some embodiments, the cell and / or subject lacks BAG3 messenger RNA or BAG3 protein expression and / or activity. The cell may be a cardiac cell, such as a cardiomyocyte. In a specific embodiment, the subject is a mammal, such as a human.
[0116] In some embodiments, the method promotes survival of cardiac cells (e.g., cardiomyocytes) in cell culture and / or in vivo. In some embodiments, the method promotes and / or restores cardiac function.
[0117] In another aspect, the present disclosure provides a method for treating a disease or illness of a subject in need, comprising administering an effective amount of the rAAV virion of the present disclosure to the subject. In some embodiments, the disease or illness is a cardiac disease or illness. Illustrative cardiac diseases include heart failure, dilated cardiomyopathy (DCM), such as BAG3-related dilated cardiomyopathy, BAG3-related myofibrillar myopathy, familial separation dilated cardiomyopathy or 1hh dilated cardiomyopathy (CMD1HH), hypertrophic cardiomyopathy, atrial fibrillation, arrhythmia, sinus node disease, hypertensive heart disease, cardiac hypertrophy, atrial fibrosis, symptomatic sick sinus syndrome (symptomatic sick sinus syndrome), atrial disease and myocardial infarction. In certain embodiments, the subject suffers from DCM or is under DCM risk. In specific embodiments, the subject suffers from cardiomyopathy, such as dilated cardiomyopathy (DCM), such as BAG3-related dilated cardiomyopathy, BAG3-related myofibrillar myopathy, familial separation dilated cardiomyopathy or 1hh dilated cardiomyopathy (CMD1HH). In a specific embodiment, the subject is a mammal, such as a human, having a loss-of-function mutation in the BAG3 gene. In a specific embodiment, the subject is a mammal, such as a human, having a BAG3 mutation (e.g., E455K). In a specific method, rAAV virions are used to treat the BAG3 protein encoded by the rAAV virions in the subject, such as in the subject's heart or cardiac tissue. In certain embodiments, rAAV virions are used to treat the BAG3 protein content detectable in the subject's heart at least twice, at least five times, at least ten times, or more.
[0118] AAV-mediated delivery of BAG3 protein to the heart can increase lifespan, prevent or attenuate cardiac cell degeneration, heart failure, scarring, reduced ejection fraction, heart arrhythmia, angina, exercise intolerance, angina pectoris (chest pain), sudden cardiac death, exertional myalgia, and cramps. AAV-mediated delivery of BAG3 protein to the heart can show improvement in common disease processes detected by using echocardiography, pathological electrocardiogram, cardiac MRI, cardiac biopsy, reduction in paroxysmal ventricular arrhythmias, and / or reduction in sudden cardiac death, or prevent the common disease processes.
[0119] The methods disclosed herein can provide efficient biodistribution in the heart. It can result in sustained expression of all or a substantial portion of cardiac cells (e.g., cardiomyocytes). It is worth noting that the methods disclosed herein can provide persistent expression of BAG3 protein throughout the life of the subject after administration of the AAV vector. In some embodiments, expression of BAG3 protein in response to treatment continues for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, or 40 years.
[0120] The present disclosure also encompasses combination therapies. Combinations of the methods of the present disclosure with standard medical treatments (e.g., corticosteroids or local decompression medications) are particularly contemplated, as are combinations with novel therapies. In some cases, a subject may be treated with a combination of steroids and / or immunosuppressants to prevent or reduce an immune response to administration of the rAAV described herein.
[0121] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered at a dose of about 1×10 β-cells per kilogram (vg) of total body weight (vg / kg) of the subject. 12 With 5×10 14 vector genomes (vg) or about 1×10 12 With 6×10 14 In some embodiments, the AAV vector is administered at a dose of about 1×10 13 With 5×10 14 In some embodiments, the AAV vector is administered at a dose of about 5×10 13 With 3×10 14 In some embodiments, the AAV vector is administered at a dose of about 5×10 13 With 1×10 14 In some embodiments, the AAV vector is administered at a dose of less than about 1×10 12 vg / kg, less than about 3×10 12 vg / kg, less than about 5×10 12 vg / kg, less than about 7×10 12 vg / kg, less than about 1×10 13 vg / kg, less than about 3×10 13 vg / kg, less than about 5×10 13 vg / kg, less than about 7×10 13 vg / kg, less than about 1×10 14 vg / kg, less than about 3×10 14 vg / kg, less than about 5×10 14vg / kg, less than about 7×10 14 vg / kg, less than about 1×10 15 vg / kg, less than about 3×10 15 vg / kg, less than about 5×10 15 vg / kg, or less than about 7×10 15 vg / kg. In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAVrh74 vector. In some cases, it may be advantageous to use an AAVrh74 vector in a higher amount than an AAV9 vector. In some embodiments, an AAV vector, such as an AAVrh.74 vector, is administered at a dose of at least about 5×10 13 vg / kg, at least about 6×10 13 vg / kg, at least about 7×10 13 vg / kg, at least about 8×10 13 vg / kg, at least about 9×10 13 vg / kg, at least about 1×10 14 vg / kg, at least about 2×10 14 vg / kg, at least about 3×10 14 vg / kg, at least about 4×10 14 vg / kg, at least about 5×10 14 vg / kg, at least about 6×10 14 vg / kg, or at least about 7×10 14 vg / kg dose.
[0122] In some embodiments, an AAV vector (e.g., an AAV9, AAVrh.74, or AAVrh.10 vector) is expressed in an amount of about 1×10 12 vg / kg, about 3×10 12 vg / kg, about 5×10 12 vg / kg, about 7×10 12 vg / kg, about 1×10 13 vg / kg, about 3×10 13 vg / kg, about 5×10 13 vg / kg, about 7×10 13 vg / kg, about 1×10 14 vg / kg, about 3×10 14 vg / kg, about 5×10 14 vg / kg, about 7×10 14 vg / kg, about 1×10 15 vg / kg, about 3×10 15 vg / kg, about 5×10 15vg / kg, or about 7×10 15 In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAVrh74 vector.
[0123] In some embodiments, an AAV vector (e.g., an AAV9, AAVrh.74, or AAVrh.10 vector) is expressed in 1×10 12 vg / kg, 3×10 12 vg / kg, 5×10 12 vg / kg, 7×10 12 vg / kg, 1×10 13 vg / kg, 3×10 13 vg / kg, 5×10 13 vg / kg, 7×10 13 vg / kg, 1×10 14 vg / kg, 3×10 14 vg / kg, 5×10 14 vg / kg, 7×10 14 vg / kg, 1×10 15 vg / kg, 3×10 15 vg / kg, 5×10 15 vg / kg, or 7×10 15 In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAVrh74 vector.
[0124] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered at a dose of about 1×10 β-cells per kilogram (vg) of total body weight (vg / kg) of the subject. 12 With 5×10 14 In some embodiments, the AAV vector is administered systemically at a dose of about 1×10 13 With 5×10 14 vg / kg. In some embodiments, the AAV vector is administered systemically at a dose of about 5×10 13 With 3×10 14 vg / kg. In some embodiments, the AAV vector is administered systemically at a dose of about 5×10 13 With 1×10 14 vg / kg. In some embodiments, the AAV vector is administered systemically at a dose of less than about 1×10 12 vg / kg, less than about 3×10 12 vg / kg, less than about 5×1012 vg / kg, less than about 7×10 12 vg / kg, less than about 1×10 13 vg / kg, less than about 3×10 13 vg / kg, less than about 5×10 13 vg / kg, less than about 7×10 13 vg / kg, less than about 1×10 14 vg / kg, less than about 3×10 14 vg / kg, less than about 5×10 14 vg / kg, less than about 7×10 14 vg / kg, less than about 1×10 15 vg / kg, less than about 3×10 15 vg / kg, less than about 5×10 15 vg / kg, less than about 7×10 15 vg / kg. In some embodiments, an AAV vector, such as an AVrh.74 vector, is administered systemically at a dose of at least about 5×10 13 vg / kg, at least about 6×10 13 vg / kg, at least about 7×10 13 vg / kg, at least about 8×10 13 vg / kg, at least about 9×10 13 vg / kg, at least about 1×10 14 vg / kg, at least about 2×10 14 vg / kg, at least about 3×10 14 vg / kg, at least about 4×10 14 vg / kg, at least about 5×10 14 vg / kg, at least about 6×10 14 vg / kg, or at least about 7×10 14 In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAVrh74 vector.
[0125] In some embodiments, an AAV vector (e.g., an AAV9, AAVrh.74, or AAVrh.10 vector) is expressed in an amount of about 1×10 12 vg / kg, about 3×10 12 vg / kg, about 5×10 12 vg / kg, about 7×10 12 vg / kg, about 1×10 13 vg / kg, about 3×10 13 vg / kg, about 5×10 13 vg / kg, about 7×1013 vg / kg, about 1×10 14 vg / kg, about 3×10 14 vg / kg, about 5×10 14 vg / kg, about 7×10 14 vg / kg, about 1×10 15 vg / kg, about 3×10 15 vg / kg, about 5×10 15 vg / kg, or about 7×10 15 In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAVrh74 vector.
[0126] In some embodiments, an AAV vector (e.g., an AAV9, AAVrh.74, or AAVrh.10 vector) is expressed in 1×10 12 vg / kg, 3×10 12 vg / kg, 5×10 12 vg / kg, 7×10 12 vg / kg, 1×10 13 vg / kg, 3×10 13 vg / kg, 5×10 13 vg / kg, 7×10 13 vg / kg, 1×10 14 vg / kg, 3×10 14 vg / kg, 5×10 14 vg / kg, 7×10 14 vg / kg, 1×10 15 vg / kg, 3×10 15 vg / kg, 5×10 15 vg / kg, or 7×10 15 In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAVrh74 vector.
[0127] In some embodiments, the AAV vector (e.g., AAV9, AAVrh.74, or AAVrh.10 vector) is administered at a dose of about 1×10 β-cells per kilogram (vg) of total body weight (vg / kg) of the subject. 12 With 5×10 14 AAV vectors are administered intravenously at a dose of about 1×10 13 With 5×10 14 vg / kg is administered intravenously. In some embodiments, the AAV vector is administered at a dose of about 5×1013 With 3×10 14 vg / kg is administered intravenously. In some embodiments, the AAV vector is administered at a dose of about 5×10 13 With 1×10 14 vg / kg is administered intravenously. In some embodiments, the AAV vector is administered at a dose of less than about 1×10 12 vg / kg, less than about 3×10 12 vg / kg, less than about 5×10 12 vg / kg, less than about 7×10 12 vg / kg, less than about 1×10 13 vg / kg, less than about 3×10 13 vg / kg, less than about 5×10 13 vg / kg, less than about 7×10 13 vg / kg, less than about 1×10 14 vg / kg, less than about 3×10 14 vg / kg, less than about 5×10 14 vg / kg, less than about 7×10 14 vg / kg, less than about 1×10 15 vg / kg, less than about 3×10 15 vg / kg, less than about 5×10 15 vg / kg, or less than about 7×10 15 vg / kg is administered intravenously. In some embodiments, an AAV vector, such as an AVrh.74 vector, is administered at a dose of at least about 5×10 13 vg / kg, at least about 6×10 13 vg / kg, at least about 7×10 13 vg / kg, at least about 8×10 13 vg / kg, at least about 9×10 13 vg / kg, at least about 1×10 14 vg / kg, at least about 2×10 14 vg / kg, at least about 3×10 14 vg / kg, at least about 4×10 14 vg / kg, at least about 5×10 14 vg / kg, at least about 6×10 14 vg / kg, or at least about 7×10 14 In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAVrh74 vector.
[0128] In some embodiments, an AAV vector (e.g., an AAV9, AAVrh.74, or AAVrh.10 vector) is expressed in an amount of about 1×10 12 vg / kg, about 3×10 12 vg / kg, about 5×10 12 vg / kg, about 7×10 12 vg / kg, about 1×10 13 vg / kg, about 3×10 13 vg / kg, about 5×10 13 vg / kg, about 7×10 13 vg / kg, about 1×10 14 vg / kg, about 3×10 14 vg / kg, about 5×10 14 vg / kg, about 7×10 14 vg / kg, about 1×10 15 vg / kg, about 3×10 15 vg / kg, about 5×10 15 vg / kg, or about 7×10 15 The dose of vg / kg was administered intravenously.
[0129] In some embodiments, an AAV vector (e.g., an AAV9, AAVrh.74, or AAVrh.10 vector) is expressed in 1×10 12 vg / kg, 3×10 12 vg / kg, 5×10 12 vg / kg, 7×10 12 vg / kg, 1×10 13 vg / kg, 3×10 13 vg / kg, 5×10 13 vg / kg, 7×10 13 vg / kg, 1×10 14 vg / kg, 3×10 14 vg / kg, 5×10 14 vg / kg, 7×10 14 vg / kg, 1×10 15 vg / kg, 3×10 15 vg / kg, 5×10 15 vg / kg, or 7×10 15 In certain embodiments, the AAV vector delivered at any of these doses is an AAV9 vector or an AAVrh74 vector.
[0130] Evidence of functional improvement, clinical benefit, or efficacy in patients may be disclosed by improvement in New York Heart Association functional class (NYHA class), echocardiography (stable or improved cardiac output, left ventricular ejection fraction, fractional shortening, left ventricular outflow tract obstruction, left ventricular wall thickness, left or right ventricular volumes, velocity time integral, ventricular relaxation time constant, regurgitant volume and reduced left ventricular end-diastolic diameter, LVEDD, and reduced right ventricular area), electrocardiography (stable or improved ST-segment changes, T wave inversion, Q waves, atrial fibrillation and / or supraventricular tachycardia), cardiac MRI, cardiac biopsy, reduction in paroxysmal ventricular arrhythmias, reduction in sudden cardiac death, and / or reduction or absence of further developed myocardial derangements.
[0131] Administration of an effective dose of the composition can be performed by standard routes in the art, including, but not limited to, systemic, local, direct injection, intravenous, intracardiac administration. In some cases, administration comprises systemic, local, direct injection, intravenous, intracardiac injection. Administration can be performed by cardiac catheterization.
[0132] In some embodiments, the present disclosure provides local and systemic administration of effective doses of rAAV and compositions of the present disclosure. For example, systemic administration can be administered to the circulatory system so that the entire body is affected. Systemic administration includes parenteral administration via injection, infusion, or implantation. The routes of administration of the compositions disclosed herein include intravenous ("IV") administration, intraperitoneal ("IP") administration, intramuscular ("IM") administration, intralesional administration, or subcutaneous ("SC") administration, or implantation of sustained-release devices (e.g., mini-osmotic pumps, reservoir preparations, etc.). In some embodiments, the methods of the present disclosure comprise administering an AAV vector of the present disclosure or a pharmaceutical composition thereof by intravenous, intramuscular, intraarterial, intrarenal, intraurethral, intracardiac, intracoronary, intramyocardial, intradermal, epidural, subcutaneous, intraperitoneal, intraventricular, or iontophoretic administration.
[0133] In particular, administration of the rAAV of the present disclosure can be achieved by using any physical method that transports the rAAV recombinant vector to the target tissue of the animal. Administration includes, but is not limited to, injection into the heart. In some embodiments, these methods include administering the rAAV in vivo into the coronary circulation, such as retrograde coronary sinus infusion.
[0134] In some embodiments, the methods of the present disclosure include intracardiac delivery. Infusion can be performed using a dedicated cannula, catheter, syringe / needle, using an infusion pump. Administration can include delivering an effective amount of rAAV virions or a pharmaceutical composition comprising rAAV virions to the heart. These can be achieved, for example, via intravenous, intramuscular, intraarterial, intrarenal, intraurethral, intracardiac, intracoronary, intramyocardial, intradermal, epidural, subcutaneous, intraperitoneal, intraventricular, or iontophoretic administration. The composition of the present disclosure can be further administered intravenously. Effects of rAAV administration
[0135] In some embodiments, administration of a rAAV of the present disclosure has a beneficial effect on a subject. life
[0136] In some embodiments, administration of a rAAV of the disclosure may increase the lifespan of a subject compared to a subject not administered a rAAV of the disclosure or compared to a baseline.
[0137] In some embodiments, administration of a rAAV of the disclosure increases lifespan by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, or at least about 500% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0138] In some embodiments, administration of a rAAV of the disclosure increases lifespan by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35% compared to a subject not administered a rAAV of the disclosure or compared to baseline. %, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, about 95% to about 100%, about 100% to about 200%, about 200% to about 300%, about 300% to about 400%, or about 400% to about 500%. Ejection fraction
[0139] In some embodiments, administration of the rAAV of the present disclosure limits reduction in ejection fraction, restores ejection fraction, and / or increases ejection fraction in a subject compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure limits reduction in ejection fraction, restores ejection fraction, and / or increases ejection fraction in a subject over time.
[0140] In some embodiments, administration of a rAAV of the disclosure restores and / or increases ejection fraction by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0141] In some embodiments, administration of a rAAV of the disclosure limits the decrease in ejection fraction to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100%, compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0142] In some embodiments, administration of a rAAV of the disclosure restores and / or increases the ejection fraction in a subject over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0143] In some embodiments, administration of a rAAV of the disclosure limits a decrease in ejection fraction in a subject over time to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100%.
[0144] In some embodiments, administration of a rAAV of the disclosure restores and / or increases ejection fraction by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15 ... %, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0145] In some embodiments, administration of a rAAV of the disclosure restores and / or increases the ejection fraction in a subject over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0146] In some embodiments, administration of a rAAV of the disclosure limits a decrease in ejection fraction to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 10%. From about 15% to about 20% of the total population, from about 15% to about 20% of the total population, from about 20% to about 35% of the total population, from about 25% to about 30% of the total population, from about 30% to about 35% of the total population, from about 35% to about 40% of the total population, from about 40% to about 45% of the total population, from about 45% to about 50% of the total population, from about 50% to about 55% of the total population, from about 55% to about 60% of the total population, from about 60% to about 65% of the total population, from about 65% to about 70% of the total population, from about 70% to about 75% of the total population, from about 75% to about 80% of the total population, from about 80% to about 85% of the total population, from about 85% to about 90% of the total population, from about 90% to about 95% of the total population, or from about 95% to about 100%.
[0147] In some embodiments, administration of a rAAV of the disclosure limits a decrease in ejection fraction in a subject over time to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about From about 15% to less than about 20%, from about 20% to less than about 35%, from about 25% to less than about 30%, from about 30% to less than about 35%, from about 35% to less than about 40%, from about 40% to less than about 45%, from about 45% to less than about 50%, from about 50% to less than about 55%, from about 55% to less than about 60%, from about 60% to less than about 65%, from about 65% to less than about 70%, from about 70% to less than about 75%, from about 75% to less than about 80%, from about 80% to less than about 85%, from about 85% to less than about 90%, from about 90% to less than about 95%, or from about 95% to about 100%. Left ventricular ejection fraction (LVEF)
[0148] In some embodiments, administration of the rAAV of the present disclosure prevents a decrease in LVEF, restores LVEF, and / or increases LVEF in a subject compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure limits a decrease in LVEF, restores LVEF, and / or increases LVEF in a subject over time.
[0149] In some embodiments, administration of a rAAV of the disclosure restores and / or increases the LVEF by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0150] In some embodiments, administration of a rAAV of the disclosure limits a decrease in LVEF to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100%, compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0151] In some embodiments, administration of a rAAV of the present disclosure restores and / or increases the LVEF in a subject over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0152] In some embodiments, administration of a rAAV of the present disclosure limits a decrease in LVEF in a subject over time to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100%.
[0153] In some embodiments, administration of a rAAV of the disclosure restores and / or increases LVEF by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 11%, about 15% to about 12%, about 16% to about 13%, about 17% to about 14%, about 18% to about 19%, about 20% to about 21%, about 25% to about 26%, about 27% to about 28%, about 29% to about 30%, about 30 ... %, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0154] In some embodiments, administration of a rAAV of the disclosure restores and / or increases the LVEF in a subject over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0155] In some embodiments, administration of a rAAV of the disclosure limits a decrease in LVEF to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 10%. From about 15% to about 20% of the total population, from about 15% to about 20% of the total population, from about 20% to about 35% of the total population, from about 25% to about 30% of the total population, from about 30% to about 35% of the total population, from about 35% to about 40% of the total population, from about 40% to about 45% of the total population, from about 45% to about 50% of the total population, from about 50% to about 55% of the total population, from about 55% to about 60% of the total population, from about 60% to about 65% of the total population, from about 65% to about 70% of the total population, from about 70% to about 75% of the total population, from about 75% to about 80% of the total population, from about 80% to about 85% of the total population, from about 85% to about 90% of the total population, from about 90% to about 95% of the total population, or from about 95% to about 100%.
[0156] In some embodiments, administration of a rAAV of the present disclosure limits a decrease in LVEF in a subject over time to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about From about 15% to less than about 20%, from about 20% to less than about 35%, from about 25% to less than about 30%, from about 30% to less than about 35%, from about 35% to less than about 40%, from about 40% to less than about 45%, from about 45% to less than about 50%, from about 50% to less than about 55%, from about 55% to less than about 60%, from about 60% to less than about 65%, from about 65% to less than about 70%, from about 70% to less than about 75%, from about 75% to less than about 80%, from about 80% to less than about 85%, from about 85% to less than about 90%, from about 90% to less than about 95%, or from about 95% to about 100%. Right ventricular ejection fraction (RVEF)
[0157] In some embodiments, administration of the rAAV of the present disclosure prevents a decrease in RVEF, restores RVEF, and / or increases RVEF in a subject compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure limits a decrease in LVEF, restores LVEF, and / or increases LVEF in a subject over time.
[0158] In some embodiments, administration of a rAAV of the disclosure restores and / or increases RVEF by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0159] In some embodiments, administration of a rAAV of the disclosure limits a decrease in RVEF to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100%, compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0160] In some embodiments, administration of the rAAV of the present disclosure restores and / or increases RVEF in a subject over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0161] In some embodiments, administration of a rAAV of the present disclosure limits a decrease in RVEF in a subject over time to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100%.
[0162] In some embodiments, administration of a rAAV of the disclosure restores and / or increases RVEF by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 11%, about 11% to about 12%, about 12% to about 13%, about 13% to about 14%, about 15% to about 16%, about 17% to about 18%, about 19% to about 20%, about 20% to about 21%, about 21% to about 22%, about 22% to about 23%, about 23% to about 24%, about 25% to about 25%, about 26% to about 27%, about 27% to about 28%, about 28% to about 29%, about 30% to about 30 ... %, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0163] In some embodiments, administration of a rAAV of the disclosure restores and / or increases RVEF in a subject over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0164] In some embodiments, administration of a rAAV of the disclosure limits a decrease in RVEF to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 10%. From about 15% to about 20% of the total population, from about 15% to about 20% of the total population, from about 20% to about 35% of the total population, from about 25% to about 30% of the total population, from about 30% to about 35% of the total population, from about 35% to about 40% of the total population, from about 40% to about 45% of the total population, from about 45% to about 50% of the total population, from about 50% to about 55% of the total population, from about 55% to about 60% of the total population, from about 60% to about 65% of the total population, from about 65% to about 70% of the total population, from about 70% to about 75% of the total population, from about 75% to about 80% of the total population, from about 80% to about 85% of the total population, from about 85% to about 90% of the total population, from about 90% to about 95% of the total population, or from about 95% to about 100%.
[0165] In some embodiments, administration of a rAAV of the present disclosure limits a decrease in RVEF in a subject over time to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about From about 15% to less than about 20%, from about 20% to less than about 35%, from about 25% to less than about 30%, from about 30% to less than about 35%, from about 35% to less than about 40%, from about 40% to less than about 45%, from about 45% to less than about 50%, from about 50% to less than about 55%, from about 55% to less than about 60%, from about 60% to less than about 65%, from about 65% to less than about 70%, from about 70% to less than about 75%, from about 75% to less than about 80%, from about 80% to less than about 85%, from about 85% to less than about 90%, from about 90% to less than about 95%, or from about 95% to about 100%. Right ventricular (RV) area
[0166] In some embodiments, administration of the rAAV of the present disclosure prevents an increase in RV area, restores RV area, and / or reduces RV area in a subject compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure prevents an increase in RV area, restores RV area, and / or reduces RV area in a subject over time.
[0167] In some embodiments, administration of a rAAV of the disclosure prevents an increase in RV area, restores RV area, and / or reduces RV area by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0168] In some embodiments, administration of a rAAV of the disclosure prevents an increase in RV area, restores RV area, and / or reduces RV area by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 11%, about 11% to about 12%, about 12% to about 13%, about 13% to about 14%, about 15% to about 16%, about 17% to about 18%, about 19% to about 20%, about 19% to about 21%, about 19% to about 22%, about 11% to about 23%, about 12% to about 24%, about 13% to about 25%, about 14% to about 26%, about 15% to about 27%, about 16% to about 28%, about 17% to about 29%, about 18% to about 20%, about 19% to about 21 From about 1% to about 10%, from about 10% to about 15%, from about 15% to about 20%, from about 20% to about 35%, from about 25% to about 30%, from about 30% to about 35%, from about 35% to about 40%, from about 40% to about 45%, from about 45% to about 50%, from about 50% to about 55%, from about 55% to about 60%, from about 60% to about 65%, from about 65% to about 70%, from about 70% to about 75%, from about 75% to about 80%, from about 80% to about 85%, from about 85% to about 90%, from about 90% to about 95%, or from about 95% to about 100%.
[0169] In some embodiments, administration of a rAAV of the disclosure prevents an increase in RV area in a subject, restores RV area, and / or reduces RV area over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0170] In some embodiments, administration of a rAAV of the disclosure prevents an increase in RV area in a subject, restores RV area, and / or reduces RV area over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 11%, about 12% to about 13%, about 14% to about 15%, about 16% to about 17%, about 18% to about 19%, about 20% to about 21%, about 21% to about 23%, about 25% to about 24%, about 26% to about 25%, about 27% to about 26%, about 28% to about 29%, about 30% to about 30%, about 30% to about 30%, about 30% to about 30%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%. Left ventricular (LV) area
[0171] In some embodiments, administration of the rAAV of the present disclosure prevents an increase in LV area, restores LV area, and / or reduces LV area in a subject compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure prevents an increase in RV area, restores RV area, and / or reduces RV area in a subject over time.
[0172] In some embodiments, administration of a rAAV of the disclosure prevents an increase in LV area, restores LV area, and / or reduces LV area by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0173] In some embodiments, administration of a rAAV of the disclosure prevents an increase in LV area, restores LV area, and / or reduces LV area by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%, about 10% to about 11%, about 11% to about 12%, about 12% to about 13%, about 13% to about 14%, about 15% to about 16%, about 17% to about 18%, about 19% to about 20%, about 19% to about 21%, about 19% to about 22%, about 11% to about 23%, about 12% to about 24%, about 13% to about 25%, about 14% to about 26%, about 15% to about 27%, about 16% to about 28%, about 17% to about 29%, about 18% to about 20%, about 19% to about 21 From about 1% to about 10%, from about 10% to about 15%, from about 15% to about 20%, from about 20% to about 35%, from about 25% to about 30%, from about 30% to about 35%, from about 35% to about 40%, from about 40% to about 45%, from about 45% to about 50%, from about 50% to about 55%, from about 55% to about 60%, from about 60% to about 65%, from about 65% to about 70%, from about 70% to about 75%, from about 75% to about 80%, from about 80% to about 85%, from about 85% to about 90%, from about 90% to about 95%, or from about 95% to about 100%.
[0174] In some embodiments, administration of a rAAV of the disclosure prevents an increase in LV area in a subject over time, restores LV area, and / or reduces the LV area by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0175] In some embodiments, administration of a rAAV of the disclosure prevents an increase in LV area, restores LV area, and / or reduces LV area in a subject over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 11%, about 12% to about 13%, about 14% to about 15%, about 16% to about 17%, about 18% to about 19%, about 20% to about 21%, about 25% to about 26%, about 27% to about 28%, about 29% to about 30%, about 30 ... 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%. Right ventricular (RV) velocity time integral (VTI)
[0176] In some embodiments, administration of the rAAV of the present disclosure limits reduction of RV VTI, restores RV VTI, and / or increases RV VTI in a subject compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure limits reduction of RV VTI, restores RV VTI, and / or increases RV VTI in a subject over time.
[0177] In some embodiments, administration of a rAAV of the disclosure restores and / or increases RV VTI by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0178] In some embodiments, administration of a rAAV of the disclosure limits the reduction in RV VTI to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0179] In some embodiments, administration of the rAAV of the disclosure restores and / or increases RV VTI in a subject over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0180] In some embodiments, administration of a rAAV of the disclosure limits the reduction in RV VTI in a subject to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% over time.
[0181] In some embodiments, administration of a rAAV of the disclosure restores and / or increases RV VTI by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35 ... %, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0182] In some embodiments, administration of the rAAV of the disclosure restores and / or increases RV VTI in a subject over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35 ... %, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0183] In some embodiments, administration of a rAAV of the disclosure limits a reduction in RV VTI to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% To less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or less than about 95% to about 100%.
[0184] In some embodiments, administration of a rAAV of the disclosure limits the reduction in RV VTI in a subject over time to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% To less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or less than about 95% to about 100%. Left ventricular (LV) velocity time integral (VTI)
[0185] In some embodiments, administration of the rAAV of the present disclosure limits reduction in LV VTI, restores LV VTI, and / or increases LV VTI in a subject compared to a subject not administered the rAAV of the present disclosure or compared to baseline. In some embodiments, administration of the rAAV of the present disclosure limits reduction in LV VTI, restores LV VTI, and / or increases LV VTI in a subject over time.
[0186] In some embodiments, administration of a rAAV of the disclosure restores and / or increases LV VTI by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0187] In some embodiments, administration of a rAAV of the disclosure limits a reduction in LV VTI to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100%, compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0188] In some embodiments, administration of a rAAV of the disclosure restores and / or increases LV VTI in a subject over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0189] In some embodiments, administration of a rAAV of the disclosure limits the reduction in LV VTI in a subject to less than about 1%, less than about 2%, less than about 3%, less than about 4%, less than about 5%, less than about 6%, less than about 7%, less than about 8%, less than about 9%, less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 55%, less than about 60%, less than about 65%, less than about 70%, at least about 75%, less than about 80%, less than about 85%, less than about 90%, less than about 95%, or less than about 100% over time.
[0190] In some embodiments, administration of a rAAV of the disclosure restores and / or increases LV VTI by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35 ... %, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0191] In some embodiments, administration of a rAAV of the disclosure restores and / or increases LV VTI in a subject over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35 ... %, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0192] In some embodiments, administration of a rAAV of the disclosure limits a reduction in LV VTI to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% To less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or less than about 95% to about 100%.
[0193] In some embodiments, administration of a rAAV of the disclosure limits a reduction in LV VTI in a subject over time to less than about 1% to less than about 90%, less than about 20% to less than about 80%, less than about 30% to less than about 80%, less than about 40% to less than about 80%, less than about 50% to less than about 80%, less than about 1% to less than about 2%, less than about 2% to less than about 3%, less than about 3% to less than about 4%, less than about 4% to less than about 5%, less than about 5% to less than about 6%, less than about 6% to less than about 7%, less than about 7% to less than about 8%, less than about 8% to less than about 9%, less than about 9% to 10%, less than about 10% to less than about 15%, less than about 15% to less than about 20%, less than about 20% To less than about 35%, less than about 25% to less than about 30%, less than about 30% to less than about 35%, less than about 35% to less than about 40%, less than about 40% to less than about 45%, less than about 45% to less than about 50%, less than about 50% to less than about 55%, less than about 55% to less than about 60%, less than about 60% to less than about 65%, less than about 65% to less than about 70%, less than about 70% to less than about 75%, less than about 75% to less than about 80%, less than about 80% to less than about 85%, less than about 85% to less than about 90%, less than about 90% to less than about 95%, or less than about 95% to about 100%. Left ventricular (LV) fibrosis
[0194] In some embodiments, administration of the rAAV of the present disclosure prevents an increase in LV fibrosis and / or reduces LV fibrosis in a subject compared to a subject not administered the rAAV of the present disclosure or compared to baseline. In some embodiments, administration of the rAAV of the present disclosure prevents an increase in LV fibrosis and / or reduces LV fibrosis in a subject over time.
[0195] In some embodiments, administration of a rAAV of the disclosure prevents an increase in LV fibrosis and / or reduces LV fibrosis by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0196] In some embodiments, administration of a rAAV of the disclosure prevents an increase in LV fibrosis and / or reduces LV fibrosis by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 11%, about 11% to about 12%, about 12% to about 13%, about 13% to about 14%, about 15% to about 16%, about 17% to about 18%, about 19% to about 20%, about 19% to about 21%, about 19% to about 22%, about 11% to about 23%, about 12% to about 24%, about 13% to about 25%, about 14% to about 26%, about 15% to about 27%, about 16% to about 28%, about 17% to about 29%, about 18% to about 20%, about 19% to about 21%, about 19% to about 22 0%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0197] In some embodiments, administration of a rAAV of the disclosure prevents an increase in LV fibrosis in a subject and / or reduces LV fibrosis over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0198] In some embodiments, administration of a rAAV of the disclosure prevents increases in LV dimensionality and / or reduces LV fibrosis in a subject over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 10% to about 25%, about 15% to about 20%, about 10% to about 25%, about 15% to about 20%, about 10% to about 25%, about 15% to about 25 ... About 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%. Right ventricular (RV) fibrosis
[0199] In some embodiments, administration of the rAAV of the present disclosure prevents an increase in RV fibrosis and / or reduces RV fibrosis in a subject compared to a subject not administered the rAAV of the present disclosure or compared to baseline. In some embodiments, administration of the rAAV of the present disclosure prevents an increase in RV fibrosis and / or reduces RV fibrosis in a subject over time.
[0200] In some embodiments, administration of a rAAV of the disclosure prevents an increase in RV fibrosis and / or reduces RV fibrosis by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0201] In some embodiments, administration of a rAAV of the disclosure prevents an increase in RV fibrosis and / or reduces RV fibrosis by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 11%, about 11% to about 12%, about 12% to about 13%, about 13% to about 14%, about 15% to about 16%, about 17% to about 18%, about 19% to about 20%, about 19% to about 21%, about 19% to about 22%, about 11% to about 23%, about 12% to about 24%, about 13% to about 25%, about 14% to about 26%, about 15% to about 27%, about 16% to about 28%, about 17% to about 29%, about 18% to about 20%, about 19% to about 21%, about 19% to about 22 0%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0202] In some embodiments, administration of a rAAV of the disclosure prevents an increase in RV fibrosis in a subject and / or reduces RV fibrosis over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0203] In some embodiments, administration of a rAAV of the disclosure prevents an increase in RV fibrosis in a subject and / or reduces RV fibrosis over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 10% to about 25%, about 15% to about 20%, about 10% to about 25%, about 15% to about 20%, about 10% to about 25%, about 15% to about 25 ... About 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%. Premature ventricular contraction (PVC)
[0204] In some embodiments, administration of the rAAV of the present disclosure prevents an increase in PVC in a subject and / or reduces PVC compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure prevents an increase in PVC in a subject and / or reduces PVC over time.
[0205] In some embodiments, administration of a rAAV of the disclosure prevents an increase in PVC and / or reduces PVC by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0206] In some embodiments, administration of a rAAV of the disclosure prevents an increase in PVC and / or reduces PVC by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, compared to a subject not administered a rAAV of the disclosure or compared to baseline. , about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0207] In some embodiments, administration of a rAAV of the disclosure prevents an increase in PVC in a subject and / or reduces the PVC over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0208] In some embodiments, administration of a rAAV of the disclosure prevents an increase in PVC in a subject and / or reduces the PVC over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%. Nonsustained ventricular tachycardia (NSVT)
[0209] In some embodiments, administration of the rAAV of the present disclosure prevents an increase in NSVT and / or reduces NSVT in a subject compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure prevents an increase in NSVT and / or reduces NSVT in a subject over time.
[0210] In some embodiments, administration of a rAAV of the disclosure prevents an increase in NSVT and / or reduces NSVT by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0211] In some embodiments, administration of a rAAV of the disclosure prevents an increase in NSVT and / or reduces NSVT by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 11%, about 15% to about 12%, about 16% to about 13%, about 17% to about 14%, about 18% to about 19%, about 20% to about 21%, about 25% to about 26%, about 27% to about 28%, about 29% to about 30%, about 30% to about 30%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%. %, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0212] In some embodiments, administration of a rAAV of the disclosure prevents an increase in NSVT in a subject and / or reduces the NSVT over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0213] In some embodiments, administration of a rAAV of the disclosure prevents an increase in NSVT in a subject and / or reduces the NSVT over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 10% to about 25%, about 15% to about 20%, about 10% to about 25%, about 15% to about 20%, about 10% to about 25%, about 15% to about 25 ... About 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%. Ectopic beats
[0214] In some embodiments, administration of the rAAV of the present disclosure prevents an increase in ectopic beats and / or reduces ectopic beats in a subject compared to a subject not administered the rAAV of the present disclosure or compared to a baseline. In some embodiments, administration of the rAAV of the present disclosure prevents an increase in ectopic beats and / or reduces ectopic beats in a subject over time.
[0215] In some embodiments, administration of a rAAV of the disclosure prevents an increase in ectopic beats and / or reduces ectopic beats by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% compared to a subject not administered a rAAV of the disclosure or compared to baseline.
[0216] In some embodiments, administration of a rAAV of the disclosure prevents an increase in ectopic beats and / or reduces ectopic beats by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 11%, about 15% to about 12%, about 16% to about 13%, about 17% to about 14%, about 18% to about 19%, about 20% to about 21%, about 25% to about 26%, about 27% to about 28%, about 29% to about 30%, about 30% to about 30%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to about 10%. %, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%.
[0217] In some embodiments, administration of a rAAV of the present disclosure prevents an increase in ectopic beats and / or reduces ectopic beats in a subject over time by at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100%.
[0218] In some embodiments, administration of a rAAV of the disclosure prevents an increase in ectopic beats and / or reduces ectopic beats in a subject over time by about 1% to about 90%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 1% to about 2%, about 2% to about 3%, about 3% to about 4%, about 4% to about 5%, about 5% to about 6%, about 6% to about 7%, about 7% to about 8%, about 8% to about 9%, about 9% to 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 35%, about 25% to about 30%, about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 100%. Numbered implementation plan
[0219] Embodiment 1. A polynucleotide comprising an expression cassette and optionally flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs), wherein the polynucleotide comprises a polynucleotide sequence encoding B-cell lymphoma 2-associated immortality gene 3 (BAG3) or a functional variant thereof operably linked to a promoter, optionally wherein the promoter is a heterologous promoter.
[0220] Embodiment 2. The polynucleotide of embodiment 1, wherein the promoter is a cardiac-specific promoter.
[0221] Embodiment 3. The polynucleotide of embodiment 1 or embodiment 2, wherein the promoter is a muscle-specific promoter.
[0222] Embodiment 4. The polynucleotide according to any one of embodiments 1 to 3, wherein the promoter is a cardiomyocyte-specific promoter.
[0223] Embodiment 5. The polynucleotide according to any one of embodiments 1 to 4, wherein the promoter is the myosin heavy chain creatine kinase 7 (MHCK7) promoter.
[0224] Embodiment 6. The polynucleotide of embodiment 5, wherein the MHCK7 promoter is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:31.
[0225] Embodiment 7. The polynucleotide of any one of embodiments 1 to 4, wherein the promoter is the cardiac troponin T (hTNNT2) promoter.
[0226] Embodiment 8. The polynucleotide of embodiment 7, wherein the hTNNT2 promoter is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:32.
[0227] Embodiment 9. The polynucleotide according to any one of embodiments 1 to 4, wherein the promoter is the human heat shock factor 70 (hHSP70) promoter.
[0228] Embodiment 10. A polynucleotide according to embodiment 9, wherein the hHSP70 promoter is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:115.
[0229] Embodiment 11. A polynucleotide according to any one of embodiments 1 to 10, wherein the expression cassette comprises exon 1 of the cardiac troponin T (hTNNT2) gene, wherein optionally the hTNNT2 promoter and exon 1 together are at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:32.
[0230] Embodiment 12. The polynucleotide according to any one of embodiments 1 to 4, wherein the promoter is a ubiquitin promoter, optionally a CMV promoter or a CAG promoter or a chicken β-globin promoter or a UBC promoter (SEQ ID NO: 116).
[0231] Embodiment 13. The polynucleotide of any one of embodiments 1 to 12, wherein the expression cassette comprises a polyadenylation signal.
[0232] Embodiment 14. The polynucleotide of embodiment 13, wherein the poly(A) signal is human growth hormone (hGH) poly(A).
[0233] Embodiment 15. The polynucleotide of any one of embodiments 1 to 14, wherein the expression cassette comprises a Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE), optionally a mutated or modified WPRE (WPRE(x)), optionally WPRE Mut6 (SEQ ID NO: 63).
[0234] Embodiment 16. The polynucleotide of any one of embodiments 1 to 15, wherein the expression cassette comprises a polynucleotide sequence encoding green fluorescent protein (GFP).
[0235] Embodiment 17. The polynucleotide according to any one of embodiments 1 to 16, wherein the B-cell lymphoma 2-associated immortality gene 3 (BAG3) or a functional fragment or variant thereof is full-length or wild-type BAG3.
[0236] Embodiment 18. The polynucleotide of any one of Embodiments 1 to 17, wherein the BAG3 is human BAG3.
[0237] Embodiment 19. A polynucleotide according to any one of embodiments 1 to 18, wherein the polynucleotide sequence encoding BAG3 is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:2.
[0238] Embodiment 20. The polynucleotide according to any one of embodiments 1 to 19, wherein the polynucleotide sequence encoding BAG3 is a human BAG3 polynucleotide.
[0239] Embodiment 21. A polynucleotide according to any one of embodiments 1 to 20, wherein the polynucleotide comprises at least about 3.0 kb, at least about 3.2 kb, at least about 3.4 kb, at least about 3.5 kb, at least about 3.7 kb, at least about 4.0 kb, at least about 4.1 kb, at least about 4.2 kb, at least about 4.3 kb, at least about 4.4 kb, at least about 4.5 kb, at least about 4.6 kb, at least about 4.7 kb, at least about 4.8 kb, or at least about 5.0 kb.
[0240] Embodiment 22. A polynucleotide according to any one of embodiments 1 to 21, wherein the polynucleotide comprises at most about 3.1 kb, at most about 3.3 kb, at most about 3.5 kb, at most about 3.7 kb, at most about 3.9 kb, at most about 4.1 kb, at most about 4.2 kb, at most about 4.3 kb, at most about 4.4 kb, at most about 4.5 kb, at most about 4.6 kb, at most about 4.7 kb, at most about 4.8 kb, at most about 4.9 kb, or at most about 5.0 kb.
[0241] Embodiment 23. The polynucleotide of any one of embodiments 1 to 22, wherein the polynucleotide comprises 4.4 kb to 5.0 kb, 4.4 kb to 4.9 kb, or 4.4 kb to 4.8 kb, wherein the polynucleotide comprises 4.0 kb to 4.6 kb, 4.0 kb to 4.5 kb, or 4.0 kb to 4.4 kb, wherein the polynucleotide comprises 4.0 kb to 4.3 kb, 4.0 kb to 4.2 kb, or 4.0 kb to 4.1 kb, or wherein the polynucleotide comprises 3.0 kb to 3.9 kb, 3.0 kb to 3.8 kb, or 3.0 kb to 3.7 kb.
[0242] Embodiment 24. The polynucleotide of any one of embodiments 1 to 23, wherein the expression cassette is flanked by 5' and 3' inverted terminal repeat sequences (ITRs).
[0243] Embodiment 25. The polynucleotide of embodiment 24, wherein the ITR is an AAV2 ITR, and / or the ITR is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 15 to 21.
[0244] Embodiment 26. A gene therapy vector comprising the polynucleotide according to any one of embodiments 1 to 25.
[0245] Embodiment 27. The vector of Embodiment 26, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) vector.
[0246] Embodiment 28. A vector according to Embodiment 27, wherein the rAAV vector is AAVrh74 or a functional variant thereof.
[0247] Embodiment 29. A vector according to embodiment 28, wherein the rAAV vector comprises a capsid protein that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 100.
[0248] Embodiment 30. A vector according to Embodiment 27, wherein the rAAV vector is AAV9 or a functional variant thereof.
[0249] Embodiment 31. A vector according to embodiment 30, wherein the rAAV vector comprises a capsid protein that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:97.
[0250] Embodiment 32. A vector according to Embodiment 27, wherein the rAAV vector is AAV6 or a functional variant thereof.
[0251] Embodiment 33. A vector according to embodiment 32, wherein the rAAV vector comprises a capsid protein that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:98.
[0252] Embodiment 34. A vector according to Embodiment 27, wherein the rAAV vector is AAVrh10 or a functional variant thereof.
[0253] Embodiment 35. A vector according to embodiment 34, wherein the rAAV vector comprises a capsid protein that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:99.
[0254] Embodiment 36. A method of treating and / or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a vector according to any one of Embodiments 26 to 35.
[0255] Embodiment 37. The method of embodiment 36, wherein the disease or condition is a cardiac disorder.
[0256] Embodiment 38. The method of embodiment 37, wherein the cardiac disorder is cardiomyopathy, optionally BAG3-associated dilated cardiomyopathy.
[0257] Embodiment 39. The method of embodiment 38, wherein the cardiomyopathy is hypertrophic cardiomyopathy (HCM) (hypertrophic).
[0258] Embodiment 40. The method of embodiment 38, wherein the cardiomyopathy is dilated cardiomyopathy (DCM).
[0259] Embodiment 41. A method according to Embodiment 37, wherein the disease or condition is a cardiac arrhythmia, optionally atrial fibrillation or sinus node disease.
[0260] Embodiment 42. The method of embodiment 37, wherein the disease or condition is heart failure.
[0261] Embodiment 43. A method according to any one of Embodiments 36 to 42, wherein the subject is a mammal.
[0262] Embodiment 44. A method according to embodiment 43, wherein the subject is a primate.
[0263] Embodiment 45. The method of embodiment 44, wherein the subject is human.
[0264] Embodiment 46. The method of any one of Embodiments 36 to 45, wherein the subject has a BAG3 gene mutation and / or reduced BAG3 expression compared to healthy subjects.
[0265] Embodiment 47. The method of any one of Embodiments 36 to 46, wherein the vector is administered by intravenous injection, intracardiac injection, intracardiac infusion and / or cardiac catheterization.
[0266] Embodiment 48. The method of any one of Embodiments 36 to 47, wherein said administration increases BAG3 expression by at least about 5%.
[0267] Embodiment 49. The method of any one of Embodiments 36 to 47, wherein said administration increases BAG3 expression by at least about 30%.
[0268] Embodiment 50. The method of any one of Embodiments 36 to 47, wherein said administration increases BAG3 expression by at least about 70%.
[0269] Embodiment 51. The method of any one of Embodiments 36 to 47, wherein said administration increases BAG3 expression by about 5% to about 10%.
[0270] Embodiment 52. The method of any one of Embodiments 36 to 47, wherein said administration increases BAG3 expression by about 30% to about 50%.
[0271] Embodiment 53. The method of any one of Embodiments 36 to 47, wherein said administration increases BAG3 expression by about 50% to about 70%.
[0272] Embodiment 54. The method of any one of Embodiments 36 to 47, wherein said administration increases BAG3 expression by about 70% to about 100%.
[0273] Embodiment 55. The method of any one of Embodiments 36 to 54, wherein said method treats and / or prevents said disease or condition.
[0274] Embodiment 56. The method of any one of Embodiments 36 to 55, wherein the method comprises administering an effective amount of the vector.
[0275] Embodiment 57. The method of any one of Embodiments 36 to 56, wherein the disease or disorder is associated with or caused by BAG3 truncation in the subject.
[0276] 58. The method of any one of embodiments 36 to 57, wherein the method comprises administering a pharmaceutical composition comprising an effective amount of the vector.
[0277] Embodiment 59. The method according to any one of embodiments 36 to 58, wherein the method comprises administering to the subject about 1×10 11 vector genomes and about 1×10 13 The vector is administered to the subject with about 1×10 12 vector genomes and about 1×10 14 of the vector, or administering to the subject about 1×10 13 vector genomes and about 1×10 15 The vector between two vector genomes.
[0278] Embodiment 60. A pharmaceutical composition comprising a carrier according to any one of embodiments 26 to 35.
[0279] Embodiment 61. A kit comprising a vector according to any one of embodiments 26 to 35 or a pharmaceutical composition according to embodiment 60 and optionally instructions for use.
[0280] Embodiment 62. Use of a vector according to any one of embodiments 26 to 35 for treating a disease or disorder, optionally according to a method according to any one of embodiments 39 to 63.
[0281] Embodiment 63. The vector of any one of embodiments 29 to 38, for use in treating a disease or disorder, optionally according to a method as in any one of embodiments 36 to 59.
[0282] Embodiment 64. A polynucleotide comprising a polynucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 107 to 116.
[0283] Embodiment 65. The polynucleotide of Embodiment 64, wherein the promoter is the MHCK7 promoter.
[0284] Embodiment 66. A polynucleotide according to embodiment 65, wherein the MHCK7 promoter is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:31.
[0285] Embodiment 67. The polynucleotide of Embodiment 64, wherein the BAG3 is human BAG3.
[0286] Embodiment 68. A gene therapy vector comprising the polynucleotide of any one of embodiments 64 to 67.
[0287] Embodiment 69. The vector of Embodiment 68, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) vector.
[0288] Embodiment 70. The vector of Embodiment 69, wherein the rAAV vector is an AArh74 vector.
[0289] Embodiment 71. The vector of Embodiment 69, wherein the rAAV vector is an AAV9 vector.
[0290] Embodiment 72. A method of treating and / or preventing a cardiac disorder in a subject identified as having a mutation or truncation in BAG3, comprising administering to the subject a vector according to any one of Embodiments 68 to 71.
[0291] Embodiment 73. The method of Embodiment 72, wherein the disease or condition is a cardiomyopathy, optionally dilated cardiomyopathy (DCM).
[0292] Embodiment 74. A method according to embodiment 72, wherein the cardiac disorder is a cardiac arrhythmia, optionally atrial fibrillation or sinus node disease, or BAG3-associated dilated cardiomyopathy.
[0293] Embodiment 75. A method according to embodiment 72, wherein the cardiac disorder is heart failure.
[0294] Embodiment 76. A method according to any one of Embodiments 72 to 75, wherein the subject is a mammal.
[0295] Embodiment 77. The method of any one of Embodiments 72 to 76, wherein the vector is administered by intravenous injection, intracardiac injection, intracardiac infusion and / or cardiac catheterization.
[0296] All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications mentioned in this specification and / or listed in this Application Data Sheet are incorporated herein by reference in their entirety.
[0297] From the foregoing it will be appreciated that, although specific embodiments of the disclosure have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the disclosure. Example Example 1: Preclinical transgene expression
[0298] test Figures 1 to 8 The vector shown in . Using cultured cardiomyocytes (e.g., induced pluripotent stem cell cardiomyocytes, iPSC-CM, AC16, HL-1, C2C12, H9C2) or other cells that can be transfected or transduced via this construct, AAV vectors or corresponding expression cassettes are tested in vitro. The expression of BAG3 transgenic protein is assessed by ELISA, immunofluorescence, immunohistochemistry and Western blot analysis. Vector DNA is detected by PCR and BAG3 transgenic mRNA is detected by qRT-PCR.
[0299] Cell-based studies using patient iPSC-derived cardiomyocytes can be extremely challenging given the difficulty in effectively maintaining BAG3KO cardiomyocytes in culture, possibly due to high levels of spontaneous apoptosis. To disclose the benefits of expression of the BAG3 transgene (following AAV vector transduction and / or transfection with vector plasmids), C2C12, AC16, and H9C2 cells and shRNA targeting BAG3 were used to mitigate / reduce the extent of apoptosis in such cells following cardiomyocyte differentiation (as measured by conventional methods (e.g., TUNEL)).
[0300] Tested after encapsulation into AAV.rh74 vector Figures 1 to 3 and Figure 8 The resulting AAV vector was tested in vitro using cultured CHO-Lec2 (a standard mutant cell that lacks 70 to 90% sialic acid in its glycoproteins and gangliosides, making the cells more sensitive to AAV transduction). Subsequent expression of BAG3 protein in transduced CHO-Lec2 cells was evaluated by Western blot analysis. Data illustrating AAVrh.74-BAG3-mediated expression of a transgenic protein (BAG3) are presented ( Fig. 9 ).
[0301] By WB, the UBC promoter produced the highest BAG3 expression in CHO-Lec2 cells, followed by hHSP70 and MHCK7. The hTnnT2 promoter ("hTnT") was found to drive lower amounts of BAG3 protein expression under these conditions. Based on these results, it can be concluded that the AAVrh.74 vector can effectively express the BAG3 protein. Example 2: Preclinical in vivo efficacy in BAG3KO and BAG3CKO mice
[0302] The selected vectors were tested in vivo using a mutant mouse cardiomyopathy model. The BAG3- / - knockout mouse model expresses a severe DCM expression type and presents one or more DCM elements of human diseases. The BAG3- / - knockout mouse (described in, e.g., Homma et al., Am J Pathol, 2006) has a single retroviral insertion that selectively destroys the mouse bag3 gene. Histological analysis of BAG3- / - mouse tissues showed abnormalities in bone and heart tissue, but no abnormalities in other parts, indicating that myopathy may be present. During the first week of life, BAG3- / - knockout mice could not be distinguished from their wild-type (+ / +) and heterozygous (+ / -) littermates. The myocardium of BAG3-null mice showed degenerative changes, with the atrium being affected to a greater extent than the ventricle. KO mice stopped gaining weight after the 12th day and appeared dwarfed relative to their littermates, and all BAG3- / - animals died on the 25th day. After 20 days of age, myofiber degeneration was found in all muscles sampled in BAG3- / - mice. H&E-stained fresh-frozen sections of muscle from BAG3- / - animals showed marked changes in myofiber size with evidence of atrophic fibers and intracellular accumulation of basophilic material. No inflammation, myonecrosis, or other dystrophic pathological abnormalities were observed in BAG3- / - muscle.
[0303] Cre-inducible cardiac-specific BAG3- / -gene knockout (also known as Bis-iCKO) can also be tested as a mouse model for moderate to severe DCM expression. This mouse model expresses one or more DCM elements of human diseases and is characterized by a BAG3 gene knockout activated by tamoxifen with cardiomyocyte specificity, and is called "Bis-iCKO" (described in, for example, Yun et al, Int J Mol Sci 2021). This mouse model allows the control of the onset of BAG3 expression loss, limits BAG3 loss in adult myocytes, and triggers the progression of molecular and functional events leading to dilated cardiomyopathy. Bis-iCKO mice are viable at birth; however, they are very susceptible to premature death from DCM and heart failure. Although 60% of Bis-iCKO mice survived to 28 days, morphological and histological analysis of Bis-iCKO hearts showed that the hearts of these mice were significantly enlarged. Echocardiography revealed that left ventricular (LV) systolic function (percentage of short-axis shortening [FS]) decreased with age in mice lacking BAG3.
[0304] The benefit of AAV-mediated BAG3 expression in the above or similar models will be demonstrated by increased survival, increased weight gain, attenuation of the normal progression of cardiomyopathy observed on echocardiogram (e.g., LVESD, LVEDD), attenuation of increases in right and / or left ventricular size, and / or attenuation of the typical decrease in left ventricular ejection fraction and / or fractional shortening. Histological analysis will show benefit by reducing the appearance of disease-related myofiber disarray, attenuating ventricular dilatation, reducing ventricular wall thinning, reducing the number of apoptotic cells, reducing DNA damage, and reducing disease-related changes in absolute cardiac size. Example 3: Rescue of heart failure in vivo after transverse aortic constriction (TAC)
[0305] AAV-BAG3 gene therapy using the selected AAV vectors described above was performed essentially as described in Knezevic et al. (JACC, 2016). The AAV expression cassette was packaged and delivered in vivo using different capsid serotypes (such as AAVrh.74 and / or AAV9).
[0306] Mouse TAC model: Transverse aortic constriction (TAC) in mice is an experimentally induced cardiac hypertrophy caused by excessive pressure load, which subsequently leads to heart failure. Compared with other experimental mouse models of heart failure, the TAC model leads to a more progressive process of reproducible cardiac hypertrophy and development of heart failure. After TAC in mice, the gradual decline in ejection fraction and other indicators of cardiac function occurred simultaneously with the gradual decline in cardiac BAG3 content. Male C57BI / 6J mice (4 months old) were anesthetized and the aortic arch was observed by performing an anterior thoracotomy to the level of the third intercostal space. Constriction was performed by suturing a silk thread between the first and second trunks of the aortic arch with a 28-gauge needle. To maintain consistency, the level of constriction was quantified by measuring the changes in Doppler velocity of the left and right carotid arteries 7 days after surgery. The peak velocity ratio of the right carotid artery to the left carotid artery can range from 5.0 to 6.5, and the ejection fraction can range from 40% to 50% after 2 weeks of TAC.
[0307] Functional Evidence of Efficacy by Echocardiography: Evidence of bioactivity and efficacy for cardiac benefit in the TAC model was assessed using transthoracic echocardiography at predefined time points, including baseline and various time intervals after TAC. To screen animals with adequate heart failure for this mouse model, the Doppler ratio of right carotid to left carotid peak velocity (RC / LC) was determined 1 week after TAC, and animals that did not meet the criteria (RC / LC of 5.0 to 6.5) were excluded from the study. In addition, echocardiography was performed 2 weeks after TAC, and animals with ejection fractions (EF) outside the 40 to 50% range were also excluded. Mice with adequate Doppler RC / EV and EF by echocardiography were then injected (either intravenously or intraorbitally) with AAV constructs overexpressing BAG3 protein or formulation buffer (FB; vehicle control) at 8 weeks after TAC. Efficacy would be evident in AAV-BAG3-treated animals as EF and FS increased significantly over time compared to the FB control group. Echocardiography will show a gradual decrease in EF and FS over time in mice injected with FB. In contrast, animals injected with AAV-BAG3 will be found to have EF and FS that return to control levels within weeks of treatment. Histological analysis will show reduced myocardial fiber disorganization.
Claims
1. A polynucleotide comprising an expression cassette and optionally flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs), wherein the polynucleotide comprises a polynucleotide sequence encoding B-cell lymphoma 2-associated immortality gene 3 (BAG3) or a functional variant thereof operably linked to a promoter, optionally wherein the promoter is a heterologous promoter.
2. The polynucleotide of claim 1, wherein the promoter is a cardiac-specific promoter.
3. A polynucleotide according to claim 1 or claim 2, wherein the promoter is a muscle-specific promoter. 4 . The polynucleotide according to any one of claims 1 to 3 , wherein the promoter is a cardiomyocyte-specific promoter.
5. The polynucleotide according to any one of claims 1 to 4, wherein the promoter is the myosin heavy chain creatine kinase 7 (MHCK7) promoter.
6. The polynucleotide of claim 5, wherein the MHCK7 promoter is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
31.
7. The polynucleotide according to any one of claims 1 to 4, wherein the promoter is the cardiac troponin T (hTNNT2) promoter.
8. The polynucleotide of claim 7, wherein the hTNNT2 promoter is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
32.
9. The polynucleotide according to any one of claims 1 to 4, wherein the promoter is the human heat shock factor 70 (hHSP70) promoter.
10. The polynucleotide of claim 9, wherein the hHSP70 promoter is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
115.
11. The polynucleotide of any one of claims 1 to 10, wherein the expression cassette comprises exon 1 of the cardiac troponin T (hTNNT2) gene, wherein optionally the hTNNT2 promoter and exon 1 together are at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
32.
12. The polynucleotide according to any one of claims 1 to 4, wherein the promoter is a ubiquitin promoter, optionally a CMV promoter or a CAG promoter or a chicken β-globin promoter or a UBC promoter (SEQ ID NO: 116).
13. The polynucleotide according to any one of claims 1 to 12, wherein the expression cassette comprises a polyadenylation signal.
14. The polynucleotide of claim 13, wherein the polyadenylation signal is human growth hormone (hGH) polyadenylation.
15. The polynucleotide of any one of claims 1 to 14, wherein the expression cassette comprises a Woodchuck Hepatitis Virus Post-transcriptional Regulatory Element (WPRE), optionally a mutated or modified WPRE (WPRE(x)), optionally WPRE Mut6 (SEQ ID NO: 63).
16. The polynucleotide according to any one of claims 1 to 15, wherein the expression cassette comprises a polynucleotide sequence encoding green fluorescent protein (GFP).
17. The polynucleotide according to any one of claims 1 to 16, wherein the B-cell lymphoma 2-associated immortality gene 3 (BAG3) or a functional fragment or variant thereof is full-length or wild-type BAG3.
18. The polynucleotide according to any one of claims 1 to 17, wherein the BAG3 is human BAG3.
19. A polynucleotide according to any one of claims 1 to 18, wherein the polynucleotide sequence encoding BAG3 is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
2.
20. The polynucleotide according to any one of claims 1 to 19, wherein the polynucleotide sequence encoding BAG3 is a human BAG3 polynucleotide.
21. A polynucleotide according to any one of claims 1 to 20, wherein the polynucleotide comprises at least about 3.0 kb, at least about 3.2 kb, at least about 3.4 kb, at least about 3.5 kb, at least about 3.7 kb, at least about 4.0 kb, at least about 4.1 kb, at least about 4.2 kb, at least about 4.3 kb, at least about 4.4 kb, at least about 4.5 kb, at least about 4.6 kb, at least about 4.7 kb, at least about 4.8 kb, or at least about 5.0 kb.
22. A polynucleotide according to any one of claims 1 to 21, wherein the polynucleotide comprises at most about 3.1 kb, at most about 3.3 kb, at most about 3.5 kb, at most about 3.7 kb, at most about 3.9 kb, at most about 4.1 kb, at most about 4.2 kb, at most about 4.3 kb, at most about 4.4 kb, at most about 4.5 kb, at most about 4.6 kb, at most about 4.7 kb, at most about 4.8 kb, at most about 4.9 kb, or at most about 5.0 kb.
23. The polynucleotide of any one of claims 1 to 22, wherein the polynucleotide comprises 4.4 kb to 5.0 kb, 4.4 kb to 4.9 kb, or 4.4 kb to 4.8 kb, wherein the polynucleotide comprises 4.0 kb to 4.6 kb, 4.0 kb to 4.5 kb, or 4.0 kb to 4.4 kb, wherein the polynucleotide comprises 4.0 kb to 4.3 kb, 4.0 kb to 4.2 kb, or 4.0 kb to 4.1 kb, or wherein the polynucleotide comprises 3.0 kb to 3.9 kb, 3.0 kb to 3.8 kb, or 3.0 kb to 3.7 kb.
24. The polynucleotide of any one of claims 1 to 23, wherein the expression cassette is flanked by 5' and 3' inverted terminal repeats (ITRs).
25. The polynucleotide of claim 24, wherein the ITR is an AAV2 ITR, and / or the ITR is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 15 to 21.
26. A gene therapy vector comprising the polynucleotide according to any one of claims 1 to 25.
27. The vector of claim 26, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) vector.
28. The vector of claim 27, wherein the rAAV vector is AAVrh74 or a functional variant thereof.
29. The vector of claim 28, wherein the rAAV vector comprises a capsid protein that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
100.
30. The vector according to claim 27, wherein the rAAV vector is AAV9 or a functional variant thereof.
31. The vector of claim 30, wherein the rAAV vector comprises a capsid protein that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
97.
32. The vector of claim 27, wherein the rAAV vector is AAV6 or a functional variant thereof.
33. The vector of claim 32, wherein the rAAV vector comprises a capsid protein that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
98.
34. The vector of claim 27, wherein the rAAV vector is AAVrh10 or a functional variant thereof.
35. The vector of claim 34, wherein the rAAV vector comprises a capsid protein that is 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
99.
36. A method of treating and / or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a vector according to any one of claims 26 to 35.
37. The method of claim 36, wherein the disease or condition is a cardiac disorder.
38. The method of claim 37, wherein the cardiac disorder is a cardiomyopathy, optionally BAG3-associated dilated cardiomyopathy.
39. The method of claim 38, wherein the cardiomyopathy is hypertrophic cardiomyopathy (HCM) (hypertrophic).
40. The method of claim 38, wherein the cardiomyopathy is dilated cardiomyopathy (DCM).
41. The method of claim 37, wherein the disease or disorder is a cardiac arrhythmia, optionally atrial fibrillation or sinus node disease.
42. The method of claim 37, wherein the disease or condition is heart failure.
43. The method of any one of claims 36 to 42, wherein the subject is a mammal.
44. The method of claim 43, wherein the subject is a primate.
45. The method of claim 44, wherein the subject is a human.
46. The method of any one of claims 36 to 45, wherein the subject has a BAG3 gene mutation and / or reduced BAG3 expression compared to a healthy subject.
47. The method of any one of claims 36 to 46, wherein the vector is administered by intravenous injection, intracardiac injection, intracardiac infusion and / or cardiac catheterization.
48. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by at least about 5%.
49. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by at least about 30%.
50. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by at least about 70%.
51. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by about 5% to about 10%.
52. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by about 30% to about 50%.
53. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by about 50% to about 70%.
54. The method of any one of claims 36 to 47, wherein the administration increases BAG3 expression by about 70% to about 100%.
55. The method according to any one of claims 36 to 54, wherein the method treats and / or prevents the disease or disorder.
56. The method of any one of claims 36 to 55, wherein the method comprises administering an effective amount of the vector.
57. The method of any one of claims 36 to 56, wherein the disease or disorder is associated with or caused by BAG3 truncation in the subject.
58. The method of any one of claims 36 to 57, wherein the method comprises administering a pharmaceutical composition comprising an effective amount of the vector.
59. The method of any one of claims 36 to 58, wherein the method comprises administering to the subject about 1×10 11 vector genomes and about 1×10 13 The vector is administered to the subject with about 1×10 12 vector genomes and about 1×10 14 of the vector, or administering to the subject about 1×10 13 vector genomes and about 1×10 15 The vector between two vector genomes.
60. A pharmaceutical composition comprising a carrier according to any one of claims 26 to 35.
61. A kit comprising a vector according to any one of claims 26 to 35 or a pharmaceutical composition according to claim 60 and optionally instructions for use.
62. Use of a vector according to any one of claims 26 to 35 for treating a disease or disorder, optionally according to a method according to any one of claims 39 to 63.
63. A vector according to any one of claims 29 to 38 for use in treating a disease or disorder, optionally according to a method according to any one of claims 36 to 59.
64. A polynucleotide comprising a polynucleotide sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 107 to 116.
65. The polynucleotide of claim 64, wherein the promoter is the MHCK7 promoter.
66. The polynucleotide of claim 65, wherein the MHCK7 promoter is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:
31.
67. The polynucleotide of claim 64, wherein the BAG3 is human BAG3.
68. A gene therapy vector comprising a polynucleotide according to any one of claims 64 to 67.
69. The vector of claim 68, wherein the gene therapy vector is a recombinant adeno-associated virus (rAAV) vector.
70. The vector of claim 69, wherein the rAAV vector is an AArh74 vector.
71. The vector of claim 69, wherein the rAAV vector is an AAV9 vector.
72. A method of treating and / or preventing a cardiac disorder in a subject identified as having a mutation or truncation in BAG3, comprising administering to the subject a vector according to any one of claims 68 to 71.
73. The method of claim 72, wherein the disease or disorder is a cardiomyopathy, optionally dilated cardiomyopathy (DCM).
74. The method of claim 72, wherein the cardiac disorder is a cardiac arrhythmia, optionally atrial fibrillation or sinus node disease, or BAG3-associated dilated cardiomyopathy.
75. The method of claim 72, wherein the cardiac disorder is heart failure.
76. The method of any one of claims 72 to 75, wherein the subject is a mammal.
77. The method of any one of claims 72 to 76, wherein the vector is administered by intravenous injection, intracardiac injection, intracardiac infusion and / or cardiac catheterization.
Citation Information
Patent Citations
BAG3 as a target for therapy of heart failure
US11236389B2
Methods of packaging multiple adeno-associated virus vectors
US20170218395A1
Bag3 compositions and methods
US20180296703A1
Optimizing bag3 gene therapy
US20210254159A1
DNA constructs for retrovirus packaging cell lines
US4861719A
